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Abstract 
Myofibroblasts are crucial for normal wound healing and tissue remodelling and play an es-
sential role in the pathogenesis of ischemic tissue fibrosis. Due to their contractile features, 
myofibroblasts support wound closure; however, overactive myofibroblasts will cause severe 
scarring that can lead to organ dysfunction. The transition of fibroblasts to myofibroblasts is 
initiated by a wide range of microenvironmental stimuli, such as mechanical stress, cytokine 
signalling or alteration of oxygen supply. However, the oxygen-dependent molecular regula-
tory mechanisms underlying the myofibroblast programme remain unclear. 
 
In this doctoral thesis, the effect of reduced oxygen availability (hypoxia) on the myofibroblast 
differentiation process was investigated in vitro. Under hypoxic conditions, decreased ex-
pression of αSMA, the signature protein of myofibroblast differentiation, and actin filament 
remodelling were paralleled by reduced cell contractility. This led to the conclusion that hy-
poxia reverts myofibroblast differentiation. Dedifferentiation of myofibroblasts was also ob-
served when RhoA activity was inhibited in normoxia. In this study, reduced RhoA activity 
was observed in hypoxia, indicating that oxygen availability influences RhoA activity and 
myofibroblast differentiation. The Rho GTPase activating protein ArhGAP29 was identified to 
be involved in fine-tuning the RhoA response in hypoxia as its expression is induced in hy-
poxia in a HIF-1α-dependent manner.  
By regulating RhoA activity, ArhGAP29 plays an important role in the MRTF/SRF signalling 
pathway and thus has a critical impact on the myofibroblast differentiation programme in hy-
poxia. The oxygenation state of tissue is of importance in the wound healing process, hence 
the presented new link between hypoxia and the regulation of the RhoA-MRTF/SRF signal-
ling axis provides both new insights into the molecular mechanisms underlying the myofibro-
blast differentiation and promising therapeutic targets for tissue remodelling and fibrosis in an 
ischemic context. 
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1 Introduction 
1.1 Oxygen homeostasis 
1.1.1 The undersupply of oxygen: hypoxia 
With rising oxygen levels on earth a billion years ago, the development of effective strategies 
to use oxygen for the metabolism preserved the survival of evolving aerobic organisms 
(Dunwoodie, 2009). Therefore, it is not surprising that the undersupply of oxygen is challeng-
ing and even life-threatening for aerobes. When the cellular oxygen demand exceeds the 
level of oxygen supply, a condition termed hypoxia occurs. Hypoxia is further defined by a 
reduced partial pressure of oxygen (pO2) compared to the physiological pO2 in the respective 
tissue (Sen, 2009). Hence, every organ and tissue has an individual physiological normoxic 
state.  
 
Hypoxia can arise from physiological and pathological circumstances. In a physiological con-
text, the development of mammalian embryos takes place in a hypoxic environment, for ex-
ample ensuring normal heart and placenta formation (Dunwoodie, 2009). Enhanced physical 
activity can also result in hypoxia if the cardiovascular system cannot cope with the in-
creased oxygen demand of exercising muscles. This is often accompanied by the switch to 
anaerobic metabolism (Garvey et al., 2012). Exposure to high altitudes and consequently the 
reduction of pO2 generally leads to physiologically induced hypoxia and further to patho-
physiological consequences such as high-altitude illness (Hackett and Roach, 2001). The 
pathological responses that hypoxia is involved in include: inflammation, wound healing, 
cancer signalling and ischemia. Disrupted blood flow, often following myocardial infarction 
(MI), results in ischemic tissue, including hypoxia. 
 
The maintenance of oxygen homeostasis by responding and adapting to reduced oxygen 
levels is important to prevent cell dysfunction and in more extreme circumstances cell death. 
These responses range from acute responses, such as enhanced ventilation and the meta-
bolic switch to anaerobic glycolysis to chronical adaption through the activation of gene tran-
scription (Michiels, 2004). This can result in the stimulation of angiogenesis and erythropoi-
esis (Michiels, 2004). There are several oxygen-sensing pathways involved in regulating the 
hypoxic response, including the hypoxia inducible factors (HIFs), the key inducers of the hy-
poxic transcriptional response (Michiels, 2004; Dunwoodie, 2009). 
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1.1.2 The structure and role of hypoxia inducible factors 
HIFs form a unique family of proteins that are essential for the transcriptional cellular re-
sponse and adaption to hypoxia. The heterodimeric DNA-binding complex HIF consists of an 
unstable α- and a stable β-subunit, also known as the aryl hydrocarbon receptor nuclear 
translocator (ARNT) (Wang et al., 1995). Three different isoforms of the oxygen-sensitive 
HIF-α subunits are known: HIF1-α, HIF-2α and HIF-3α. HIF-1α was the first described iso-
form. Semenza and colleagues discovered it while they were studying the hypoxic induction 
of erythropoietin (EPO), a hormone crucial for erythrocyte production (Semenza and Wang, 
1992; Wang and Semenza, 1995). 
 
Both HIF-1α and HIF-2α are essential for normal embryogenesis. Genetic knockout of HIF-
1α in mice results in impaired vascularisation, severe defects of the neural tube and heart, 
causing lethality early in gestation (Ryan et al., 1998; Iyer et al., 1998). HIF-2α deficiency is 
also lethal as HIF-2α knockout mouse embryos develop brachycardia and vascular defects 
(Tian et al., 1998; Peng et al., 2000). Compared to HIF-1α and HIF-2α, the biological role of 
HIF-3α is yet to be elucidated. However, studies in mice report a role of HIF-3α in lung de-
velopment, as the lack of HIF-3α results in branching defects and fewer alveoli (Huang et al., 
2013). 
There are two paralogs of the HIF-β subunit described: ARNT and ARNT2 (Graham and 
Presnell, 2017). Unlike the highly oxygen-dependent HIF-α subunits, the HIF-β subunits are 
not responsive to oxygen (Weidemann and Johnson, 2008). HIF-1α and ARNT are ubiqui-
tously expressed, whereas HIF-2α, HIF-3α, and ARNT2 are expressed in a cell restricted 
manner (Rankin and Giaccia, 2008). 
 
The α and β subunits of the HIF-heterodimer consist of the basic helix-loop-helix PER-ARNT-
SIM (bHLH-PAS) domains for the interaction of the subunits and DNA binding (Fig. 1), thus 
allowing them to bind hypoxia-responsive elements (HREs, core sequence G/ACGTG) in or 
outside promotor regions of its target genes (Schofield and Ratcliffe, 2005). The HIF-α do-
main structure includes two transactivation domains (C-TAD and N-TAD) and an oxygen-
dependent degradation domain (ODDD), essential for transcriptional activity (Pugh et al., 
1997; Huang et al., 1998). The ODDD of HIF-1α and HIF-2α possesses conserved proline 
residues (Pro402/Pro564 for HIF-1α and Pro405/Pro531 for HIF-2α), which enables the HIF-
α domain to interact with the von Hippel-Lindau tumour suppressor protein (pVHL) via trans-
prolyl-4-hydroxylation (Schofield and Ratcliffe, 2005; Haase, 2012). Furthermore, both HIF-
1α and HIF-2α have a highly conserved asparagine (Asn803 for HIF-1α, Asn847 for HIF-2α) 
within the C-TAD (Dengler et al., 2014). 
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Figure 1: Schematic representation of the HIF-1α and HIF-β domain structure. The hypoxia in-
ducible factor (HIF)-1α and HIF-1β subunits have structural similarities as they both consist of the ba-
sic helix-loop-helix PER-ARNT-SIM (bHLH-PAS) domains, which are important for DNA binding and 
interaction. HIF-1α is hydroxylated at the proline residues Pro402 and Pro564 that are located in the 
oxygen-dependent degradation domain (ODDD), and at an asparagine (Asn803) within the C-terminal 
transactivation domain (C- TAD).  
 
1.1.3 Oxygen sensing: regulation of HIF-1α  
The regulation of HIF-1α relies on an oxygen-dependent mechanism. Under normoxic condi-
tions, the HIF-1α subunit is hydroxylated by PHDs, resulting in ubiquitination and protea-
somal degradation. 
PHDs are Fe(II) and 2-oxoglutarate (2-OG)-dependent dioxygenases, that require ascorbate 
and molecular oxygen for catalytic activity (Myllyharju and Kivirikko, 1997). The oxygen at-
oms are utilised for oxidative decarboxylation of 2-OG, resulting in CO2 and succinate and for 
the integration into a peptidyl proline of HIF-1α, forming a hydroxyproline (McNeill et al., 
2002; Hewitson et al., 2002; Berra et al., 2006; Kaelin and Ratcliffe, 2008). The prolyl hy-
droxylase domain (PHD) enzymes PHD1, PHD2 and PHD3 hydroxylate the HIF-1α proline 
residues Pro402 and Pro564 if oxygen and the cofactors are available (Semenza, 2009). The 
hydroxylation of the proline residues allows the pVHL ubiquitin–protein E3 ligase complex to 
bind resulting in ubiquitination and proteasomal degradation of HIF-1α (Fig. 2) (Semenza, 
2009). The constant degradation of the HIF-1α after translation leads to a short half-life and 
thus to low basal levels of HIF-1α protein in normoxia (Berra et al., 2001). Furthermore, the 
C-TAD of HIF-1α contains an asparagine residue (Asn803). In normoxic conditions, Asn803 
is hydroxylated by factor inhibiting HIF (FIH) hindering the co-activator p300 to bind and to 
initiate transcriptional activity (Schofield and Ratcliffe, 2005; Kaelin and Ratcliffe, 2008).  
 
Hypoxia inhibits the oxygen-dependent PHD-mediated hydroxylation (Semenza, 2009). The 
effect of hypoxia on PHDs can also be generated artificially, for example with the 2-
oxoglutarate analog dimethyloxalylglycine (DMOG), which is a competitive inhibitor for the 
PHDs (Jaakkola et al., 2001; Weidemann and Johnson, 2008). If not degraded, HIF-1α 
translocates into the nucleus and forms a stable complex with the HIF-1β subunit. The 
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complex binds to the core sequence of the HREs, together with the transcriptional 
coactivators p300 and the CREB-binding protein (CBP), resulting in the transcription of HIF 
target genes (Schofield and Ratcliffe, 2005). Over 100 HIF target genes are known, many of 
them are involved in regulatory processes such as cell growth and survival, differentiation, 
proliferation, metabolism and angiogenesis (Weidemann and Johnson, 2008). HIF target 
genes include EPO, which stimulates erythropoiesis, the vascular endothelial growth factor 
(VEGF) to restore the oxygen and nutrition supply by vascularisation and the glucose 
transporter-1 (GLUT-1), upregulating the cellular glucose transport in hypoxia (Wang et al., 
1995; Hayashi et al., 2004; Desmoulière et al., 2005; Hong et al., 2014; Darby and Hewitson, 
2016). 
 
 
Figure 2: Illustration of HIF regulation in normoxia and hypoxia. In normoxia the hypoxia inducible 
factor (HIF)-1α is hydroxylated by prolyl hydroxylase domain enzymes (PHDs) in a 2-oxoglutarate (2-
OG) and oxygen-dependent manner, resulting in ubiquitination (Ub) by the von Hippel-Lindau tumour 
suppressor protein E3 ubiquitin ligase complex (pVHL) followed by proteasomal degradation. Under 
hypoxic conditions, the PHD-mediated hydroxylation is inhibited. HIF-1α translocates into the nucleus 
and forms a stable complex with the HIF-1β subunit. Together with the transcriptional coactivators 
p300 and the CREB-binding protein (CBP), the HIF-1 complex binds to the core sequence of the hy-
poxia responsive element (HRE) which activates the transcription of HIF target genes. 
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1.2 The myofibroblast 
1.3 Morphological characteristics of the myofibroblast 
Myofibroblasts display a unique specialised cell type, crucial for wound repair and tissue re-
modelling, but also involved in pathological conditions like fibrosis. In the early 1970s, Gab-
biani and colleagues first described the myofibroblast phenotype as an activated fibroblast in 
granulation tissue of dermal wounds (Gabbiani et al. 1971). Early research defined myofibro-
blasts by their ultrastructural morphology as an intermediate phenotype between common 
fibroblasts and smooth muscle (SM) cells (Majno et al., 1971; Gabbiani et al., 1971). Indeed, 
the ultrastructural characteristics, such as dense microfilament bundles are quite similar to 
SM cells, whilst also showing fibroblast features, such as a prominent rough endoplasmic 
reticulum (Gabbiani et al., 1971). The most striking feature that separated myofibroblasts 
from fibroblasts was the ability to contract tissue (Gabbiani et al., 1971). The microfilament 
bundles of the myofibroblast end in the fibronexus, that are also indicated as focal adhesions 
(Dugina et al., 2001; Gabbiani, 2003). Focal adhesions form a mechanotransduction com-
plex, allowing the myofibroblast to transfer the generated contractile force to the extracellular 
matrix (ECM) by connecting intracellular actin and extracellular fibronectin domains via 
transmembrane integrins (Gabbiani, 2003). This feature allows the myofibroblast to contract 
the surrounding ECM, promoting tissue remodelling and scar formation. 
 
Furthermore, it has been reported that myofibroblasts, similar to SM cells, are connected via 
functional gap junctions (Gabbiani et al., 1978; Spanakis et al., 1998; Tomasek et al., 2002). 
With the development of advanced techniques, myofibroblast specific immunohistochemical 
markers were established. The most commonly used marker to distinguish myofibroblasts 
from fibroblasts is α smooth muscle actin (αSMA), which is expressed de novo by myofibro-
blasts and represents a typical actin isoform of vascular SM cells (Gabbiani, 2003; Hinz, 
2007). Another myofibroblast marker is the contractility-promoting gene transgelin (Tagln or 
known as SM22α) (Scharenberg et al., 2014; Dolivo et al., 2017). Transgelin is an early SM 
differentiation marker, however, it is also likely to be present in fibroblasts, where it is regu-
lated in a TGF-β-driven manner (Assinder et al., 2009). The actin-binding protein Tagln is 
involved in actin cytoskeleton remodelling, promoting cell motility and migration, as well as 
being involved in developmental processes such as the closure of the ventral body wall (Yu 
et al., 2008; Elsafadi et al., 2016; Aldeiri et al., 2017). 
 
In addition, traditional SM cell markers, such as SM myosin heavy chain, smoothelin and h-
caldesmon are used as negative labels of myofibroblasts (Darby et al., 2016). However, the 
distinction of myofibroblasts can be challenging, as some cells in vivo show typical character-
istics of myofibroblasts but are negative for αSMA. These cells are called protomyofibroblasts 
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and are predominantly present in specialised normal connective tissue (such as lung alveolar 
septa) or in early granulation tissue (open wounds); following activation, protomyofibroblasts 
become fully differentiated myofibroblasts (Tomasek et al., 2002).  
 
1.3.1 Fibroblast to myofibroblast differentiation 
The differentiation of a fibroblast to a myofibroblast is both a complex and an enigmatic proc-
ess. The detailed molecular mechanisms underlying this differentiation process are not fully 
understood (Baum and Duffy 2011). The principal of myofibroblast differentiation relies on a 
defined pattern that is independent of their heterogeneous origin (Hinz et al. 2007). Although 
it is acknowledged that myofibroblasts predominantly originate from tissue-resident fibro-
blasts, other organ-specific progenitor cells have been reported (Hinz et al. 2007). For exam-
ple, myofibroblasts found in the liver can differentiate from hepatic stellate cells (HSCs) and 
epithelial cells, whereas myofibroblasts in lung tissue derive from endothelial-to-
mesenchymal transition (Hinz et al. 2007). In general, fibroblasts respond to stress factors 
such as mechanical tension, cytokines and altered oxygenation with the initiation of the myo-
fibroblast programme (Hinz 2007; Tomasek et al. 2002). Under healthy, physiological condi-
tions, the main function of fibroblasts is the maintenance and synthesis of the ECM by inte-
grating collagens, fibronectin and proteoglycans (McAnulty 2007; Nagalingam et al. 2018). 
The synthesised, cross-linked ECM also protects the fibroblasts from mechanical stress, ex-
cept during ECM remodelling during tissue injury (Hinz et al. 2007; Tomasek et al. 2002).  
 
Fibroblasts respond to mechanical changes of their microenvironment with the formation of 
stress fibers, resulting in a protomyofibroblast phenotype, an intermediate differentiation 
stage towards the mature myofibroblast (Fig. 3) (Tomasek et al. 2002). The protomyofibro-
blasts can further be stimulated to differentiate into myofibroblasts. Cell contact with rigid 
surfaces, like conventional plastic culture dishes, is also inducing a mechanical stress stimu-
lus for fibroblasts. Thus, the protomyofibroblast represents a commonly observed phenotype 
of nearly all fibroblasts cultured on plastic surfaces and in the presence of foetal calf serum 
(Tomasek et al., 2002; Hinz, 2007). Protomyofibroblasts are able to exert low contractile 
forces, but they do not contain αSMA-positive stress fibers like the fully differentiated myofi-
broblast (Tomasek et al. 2002). The de novo expression of αSMA and its incorporation into 
actin stress fibers enhances the contractility and finally hallmarks the completion of myofi-
broblast differentiation (Fig. 3) (Hinz 2007). The contractile forces derive from actin-myosin 
interaction of the stress fibers (Parizi et al., 2000). The developed forces of the contracting 
myofibroblasts are transferred to the surrounding ECM via focal adhesions (Dugina et al., 
2001; Gabbiani, 2003; Bochaton-Piallat et al., 2016). Focal adhesions are present in proto-
myofibroblasts and further develop to ‘supermature’ focal adhesions in myofibroblasts (Goffin 
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et al. 2006; Yeung et al. 2005). These ‘supermature’ focal adhesions contribute to the cell 
contraction due to their strong ECM adhesion (Rønnov-Jessen and Petersen, 1996; 
Tomasek et al., 2002; Hinz and Gabbiani, 2003; Hinz et al., 2003; Goffin et al., 2006). 
Figure 3: Illustration of the myofibroblast differentiation principle. Stress factors, such as me-
chanical tension lead to a fibroblast to protomyofibroblast differentiation. Protomyofibroblasts form 
stress fibers that terminate in the focal adhesion sites. Additional microenvironmental stimuli, such as 
transforming growth factor-β (TGF-β), promote the myofibroblast differentiation. Myofibroblasts ex-
press α smooth muscle actin (αSMA) de novo, which is incorporated into stress fibers terminating in 
large ‘supermature’ focal adhesions. Enhanced contractile forces are characteristic for the differenti-
ated myofibroblasts. The myofibroblast contributed contractility and extracellular matrix components, 
i.e. splice variant extra domain-A (ED-A) fibronectin are essential for tissue remodelling. Dedifferentia-
tion of the myofibroblast phentotype to fibroblasts (dashed arrow) is controversially discussed in the
literature. Figure modified from Tomasek et al. (2002).
Mechanical stress alone is not enough to initiate myofibroblast differentiation. The presence 
of the cytokine transforming growth factor-β 1 (TGF-β) is necessary for myofibroblast differ-
entiation (Hinz, 2010). Impaired myofibroblast differentiation on stiff substrates is caused by 
inhibition of TGF-β (Hinz 2010). TGF-β is referred to as the major regulator of the myofibro-
blast differentiation and induces the expression of αSMA (Desmoulière et al., 1993). In addi-
tion, TGF-β and its downstream effectors are thought to be the key inducer of fibrosis (Stem-
pien-Otero et al., 2016; Meng et al., 2016). The TGF-β-signalling is rather complex and is 
regulated via Smad-dependent, canonical pathways or Smad-independent, non-canonical 
pathways (Zhang, 2009; Meng et al., 2016).  
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Once activated, the homodimer form of TGF-β binds to the TGF-β receptor 2 (TGFR2) and 
thereby activates the TGF-β receptor 1 (TGFR1). This results in the phosphorylation of the 
effector proteins Smad2 and Smad3, which form a complex with Smad4. The complex 
translocates into the nucleus, where Smad3 induces the transcription of genes activating the 
myofibroblast programme (Meng et al., 2016). In addition to the described Smad-dependent 
pathway, TGF-β also induces Rho GTPase signalling, mitogen-activated protein kinase 
(MAPK) pathways and phosphatidylinositol 3 (PI-3)-kinase-Akt signalling (Zhang, 2009; Beier 
and Loeser, 2010; Carthy, 2018). Rho GTPases downstream signalling is further involved in 
the myocardin-related transcription factor (MRTF) / serum response factor (SRF) pathway, 
the key inducer for the myofibroblast programme and fibrosis (Small, 2012). 
 
The reorganisation of the actin cytoskeleton represents the most important step of 
myofibroblast differentiation, leading to stress fiber formation and further to the contractile 
phenotype. Besides the mechanical forces, myofibroblasts also contribute to tissue 
remodelling by synthesising ECM components, such as collagens and the fibronectin splice 
variant extra domain-A (ED-A) (Hinz, 2007). Once the tissue is successfully repaired, 
myofibroblasts undergo apoptosis or remain in the scarred tissue (Willems et al., 1994; 
Desmoulière et al., 1995). Reversible myofibroblast differentiation resulting in a quiescent 
fibroblast has been considered in the literature (Hecker et al., 2011; Darby et al., 2014). 
However, the detailed mechanisms of this are still unknown. 
 
1.3.2 Tissue hypoxia and fibrosis 
Dysfunction of the complex myofibroblast differentiation signalling network can cause patho-
logical conditions such as excessive scarring, fibrosis, as well as tissue and organ dysfunc-
tion (Tomasek et al., 2002; Hinz et al., 2012). The essential factors that promote excessive 
scarring after wound repair still need to be understood, however hypoxia has been sug-
gested to play a critical role in myofibroblast dysfunction (Kischer et al., 1982; Darby and 
Hewitson, 2016). Normal wound healing can be divided into three major processes: inflam-
mation, proliferation and tissue remodelling (Singer and Clark, 1999; Darby et al., 2014).  
 
Oxygen plays a crucial role for normal wound healing. Tissue injury causes a sudden loss of 
perfusion, hence a lack of oxygen and nutrient supply. Wound healing proceeds under hy-
poxia (Darby et al., 2014). The HIF pathway activates the transcription of genes important for 
the inflammatory response, restoration of the vascularisation and the recovery of normoxia 
(Hong et al., 2014). Studies on HIF-1 deficient mice show hindered dermal wound healing 
due to delayed myofibroblast differentiation (Musyoka et al., 2013). Polymorphisms in the 
HIF-1α gene have been reported to be involved in systemic sclerosis, a connective tissue 
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disease, within the European Caucasian population (Wipff et al., 2009). In physiological con-
ditions, successful tissue repair leads to the decrease of αSMA and completion of the myofi-
broblast-mediated contraction (Desmoulière et al., 1995). Progressing scar formation is ac-
companied by increased cell apoptosis, especially affecting the myofibroblast population in 
the restored tissue (Desmoulière et al. 1995). However, myofibroblasts in the heart are re-
ported to remain in myocardial scars (Willems et al. 1994). In pathological disorders, the con-
tractile activity of myofibroblast in fibrotic tissue proceeds, causing tissue deformation (Des-
moulière et al., 1995). 
 
Even though transient hypoxia is critical for the activation of genes necessary to repair the 
damaged tissue, persistent hypoxia is detrimental for the healing of ischemic wounds (Darby 
and Hewitson, 2016). It has been speculated, that overactive contraction in scarring disor-
ders, like hypertrophic scars and keloids, leads to microvascular occlusion and thus to 
chronic hypoxia (Darby and Hewitson, 2016). Chronic HIF-1α activity, accompanied with 
constant increased profibrotic factors (such as TGF-β) has been associated with fibroprolif-
erative disorders, such as keloids and sclerosis (Zhang et al., 2003; Distler et al., 2007; 
Darby and Hewitson, 2016). Taken together, these findings emphasise the important influ-
ence of hypoxia on fibrotic diseases, however the molecular link between tissue oxygenation 
(i.e. hypoxia) and myofibroblast differentiation is not fully understood. 
 
1.4 Rho GTPases 
1.4.1 The Rho GTPase family 
Rho GTPases are part of the Ras-like superfamily of small GTPases and consist of 20 
known members in mammals (Vega and Ridley, 2008). These are divided into eight sub-
groups based on their shared amino-acid-sequence identity (Fig. 4) (Vega and Ridley, 2008). 
Ras-like proteins are found to be highly conserved among eukaryotes (Boureux et al., 2007). 
One of the biggest subfamilies of the Ras-like GTPases is the Rho family, which includes the 
well studied members RhoA (Ras homolog gene family member A), Rac1 (Ras-related C3 
botulinum toxin substrate 1) and Cdc42 (Cell division control protein 42 homolog) 
(Tcherkezian and Lamarche-Vane, 2007; Heasman and Ridley, 2008). The members of the 
Rho family are small proteins, consisting of 190-250 amino acid residues including the 
GTPase domain plus N- and C-terminal extensions (Wennerberg and Der, 2004). The 
GTPase domain consists of a Rho insert domain, which is characteristic of the Rho family 
(Valencia et al., 1991; Wennerberg and Der, 2004). The Rho GTPases family members 
RhoA, RhoB and RhoC share a high amino acid sequence identity (87%) and form the 
RhoA-related subfamily (Wennerberg and Der, 2004; Vega and Ridley, 2018). Furthermore, 
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the RhoGTPase family can be divided into typical Rho GTPases and atypical Rho GTPases. 
Typical Rho GTPases, like, RhoA, Rac1 and Cdc42 are regulated by GTPase-activating pro-
teins (GAPs) and guanine nucleotide-exchange factors (GEFs), whereas atypical Rho 
GTPases, like RhoE and RhoU, are regulated by phosphorylation, protein stability and gene 
expression (Heasman and Ridley, 2008). 
 
 
Figure 4: The Rho GTPase family. The phylogenetic tree is based on the shared amino-acid se-
quence identity of the shown Rho GTPases. The 20 members of the Rho GTPase family can be di-
vided into eight subfamilies. Furthermore, the family members are assigned to atypical and classical 
Rho GTPases due to their mode of regulation. The figure is taken from Heasman and Ridley (2008). 
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1.4.2 The regulation of Rho GTPases 
Typical Rho GTPase switch between an active GTP-bound state and an inactive GDP-bound 
state (Fig. 5). Three proteins regulate this cycle: GEFs (Rossman et al., 2005), GAPs 
(Tcherkezian and Lamarche-Vane, 2007), and guanine nucleotide-dissociation inhibitors 
(GDIs) (Dovas and Couchman, 2005). GEFs catalyse the exchange of GDP to GTP, thus 
activate the Rho GTPases. GAPs stimulate the GTP hydrolysis, leading to the conversion to 
the inactive GDP-bound state (Vega and Ridley, 2008). 
 
Both active and inactive forms of Rho GTPases can interact with membranes via posttran-
scriptional C-terminal modification (Bishop and Hall, 2000). GDIs are involved in the stabilisa-
tion of the GDP-bound state, maintaining the inactive Rho GTPases in the cytoplasm, pre-
venting interaction with the membrane and the exchange of GDP to GTP (Olofsson, 1999; 
Bishop and Hall, 2000; Tcherkezian and Lamarche-Vane, 2007). In addition to this cycling 
regulation, it is known that Rho GTPases are also directly regulated by phosphorylation and 
ubiquitination (Lang et al., 1996; Wang et al., 2002). Activated Rho GTPases can activate 
downstream effectors, such as kinases, to induce a specific cellular response and behaviour 
(Vega and Ridley, 2008). RhoGTPases are involved in many cellular regulatory mechanisms, 
like the remodelling of the actin cytoskeleton, cell growth control, membrane trafficking and 
transcriptional activation (Villalonga and Ridley, 2006; Ridley, 2006). 
 
 
Figure 5: Schematic of the Rho GTPase regulation. Rho GTPases cycle between an inactive, 
GDP-bound conformation and an active, GTP-bound conformation. GTPase-activating proteins 
(GAPs) catalyse the hydrolysis of the GTP to the GDP-bound state. Inactive Rho GTPases can be 
sequestered in the cytoplasm by guanine nucleotide-dissociation inhibitors (GDIs). The activation of 
Rho GTPases is regulated by guanine nucleotide-exchange factors (GEFs), which promote the ex-
change of GDP to GTP. Once activated, Rho-GTP can regulate cell responses through downstream 
effectors. 
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1.4.3 The Rho family member RhoA 
The ubiquitously expressed Rho family member RhoA was the first isoform discovered in the 
1980s while studying ras genes in Aplysia (Madaule and Axel, 1985). RhoA shares similarity 
with the isoforms RhoB and RhoC. Although they are similar, they differ in their expression 
profiles, cellular localisation and cellular function. RhoA is mainly responsible for actin-
myosin contractility and actin stress fiber formation, whereas RhoB is involved in cell survival 
and cytokine trafficking and RhoC plays an important role in cell locomotion (Wheeler and 
Ridley, 2004). The main characteristic of Rho GTPases, the regulation of stress fibers, was 
first introduced by Chardin and colleagues through studies on Clostridium botulinum C3 
toxin, a Rho inhibitor (Chardin et al., 1989). Treating cells with the toxic exoenzyme Clostrid-
ium botulinium C3 resulted in dissembled stress fibres due to the toxin´s characteristic ADP-
ribosylation of Rho GTPases (Chardin et al., 1989). This highlights the crucial role of Rho in 
the regulation of the actin cytoskeleton (Chardin et al., 1989). The important role of RhoA in 
stress fiber formation was further demonstrated by microinjection of RhoA into fibroblasts, 
resulting in excessive stress fiber formation (Paterson et al., 1990).  
 
The functional role of RhoA was identified through mutant overexpression studies and Rho 
inhibitor experiments in vitro, which however may evoke off-target effects affecting other Rho 
GTPases (Zhou and Zheng, 2013). Whereas genetic ablation of RhoB (Liu et al., 2001) and 
RhoC (Hakem et al., 2005) has no effect on normal mouse development, the role of RhoA in 
vivo is less understood (Jackson et al., 2011). A knockout mouse model of RhoA is not avail-
able (Vega and Ridley, 2007). However, studies on chicken embryo development have re-
vealed that loss of basal RhoA activity results in the disruption of epithelial cell-basement 
membrane interaction and hence in a disturbed epithelial-mesenchymal transition (Nakaya et 
al., 2008). These findings imply that RhoA is the most important member of the Rho subfam-
ily. 
 
1.4.3.1 RhoA downstream signalling and its role in actin reorganisation 
The actin cytoskeleton is essential for a wide range of cellular processes, including cell mor-
phology, cell migration and cell division (Hall, 1998). Cellular actin exists as monomeric 
globular actin (G-actin) and filamentous actin (F-actin). The transition of G-actin to F-actin is 
mediated by ATP to ADP hydrolysis. This leads to an actin treadmilling mechanism where 
monomeric actin attaches in the ATP-bound state to the fast growing, barbed (+) end of the 
actin filaments, whereas actin dissembles at the pointed (-) end in an ADP-bound state (Pol-
lard, 1986; Carlier, 1990; Lee and Dominguez, 2010). Actin dynamics are characterised by 
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rapid turnover of F-actin (Riento and Ridley, 2003; Lee and Dominguez, 2010). RhoA medi-
ates actin polymerisation by multiple effectors, among them the Rho-associated protein 
kinase (ROCK) and the mammalian diaphanous-related (mDia) formin pathways (Bishop and 
Hall, 2000; Olson and Nordheim, 2010). ROCK phosphorylates several proteins that are in-
volved in the assembly and contraction of actin filaments, such as LIM kinase (LIMK) (Riento 
and Ridley, 2003). This phosphorylation enables LIMK to inhibit the actin-binding and -
depolymerizing protein cofilin via phosphorylation (Maekawa et al., 1999; Riento and Ridley, 
2003). Inactiviation of cofilin induces the formation and stabilisation of actin filaments (Barba-
cid, 1987; Arber et al., 1998; Bishop and Hall, 2000; Bernard, 2007). 
 
In addition, ROCK regulates actin-myosin interaction (Bishop and Hall, 2000). The contractil-
ity of non-muscle cells is controlled by the phosphorylation of the myosin light chain (MLC) of 
myosin II (Amano et al., 1996). The phosphorylation of MLC is regulated by the calcium-
dependent MLC kinase (MLCK) and the MLC phosphatase (MLCP) (Riento and Ridley, 
2003). ROCK is known to phosphorylate MLC (Amano et al., 1996). ROCK also interacts 
with the myosin-binding subunit (MBS) of the MLCP (Riento and Ridley, 2003). Phosphoryla-
tion of MBS by ROCK results in MLCP inactivity accompanied by enhanced phosphorylation 
of MLC and consequently increased actomyosin assembly and enhanced cell contractility 
(Kimura et al., 1996; Bishop and Hall, 2000; Riento and Ridley, 2003).  
 
Besides ROCK, mDia can also promote actin assembly downstream of active RhoA. When 
activated by RhoA, mDia regulates actin polymerisation at the barbed end of actin filaments. 
The formation of stress fibers requires the concerted activation of both ROCK and mDia as 
both dominant negative mutant experiments of either ROCK or mDia individually resulted in 
suppression of stress fibers and focal adhesion formation (Nakano et al., 1999). The Rho-
mediated G-actin to F-actin turnover (via ROCK or mDia) also links actin dynamics to gene 
transcription (Hill et al., 1995; Miralles et al., 2003). G-actin binds MRTF and sequesters it in 
the cytoplasm (Miralles et al., 2003). Actin polymerisation frees the MRTF from G-actin and 
promotes the translocation of MRTF into the nucleus. In the nucleus, MRTF activates SRF, 
which is bound to the serum response element (SRE). This consequently activates the tran-
scription of SRF target genes such as αSMA and Tagln, that are involved in the myofibro-
blast programme and fibrosis (refer to chapter 1.3.1 and 1.3.2) (Small, 2012).  
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1.4.4 The Rho GTPase activating protein ArhGAP29  
Since the first discovery of a RhoGAP by Garrett and colleagues three decades ago, the 
family of known RhoGAPs continuously grows (Garrett et al., 1989). Approximately 59 to 70 
RhoGAP domain proteins are encoded by the human genome (Tcherkezian and Lamarche-
Vane, 2007). The number of known RhoGAPs exceeds the number of Rho GTPases that 
they control (Lamarche and Hall, 1994; Tcherkezian and Lamarche-Vane, 2007). The reason 
for this is not apparent, however over the decades the scientific community has provided 
several possible explanations (Tcherkezian and Lamarche-Vane, 2007). Most likely, 
RhoGAPs do not regulate one specific Rho GTPase, but they might also act as a scaffolding 
protein to integrate signals from a number of pathways (Tcherkezian and Lamarche-Vane, 
2007).  
 
 
Figure 6: Schematic overview of the ArhGAP29 regulatory pathway. YAP (yes-associated protein) 
can promote the transcriptional activation of ArhGAP29. The microRNA (miR)-1291 is able to inhibit 
ArhGAP29 mRNA. ArhGAP29 protein levels can be regulated by Ras-related GTPase Rap1 effectors 
Rasip (ras-interacting protein) 1 and Radil (ras-association and dilute domain-containing protein) 
pathways. In addition, ArhGAP29 acts as an effector of Ras-related GTPase Rap2. ArhGAP29 nega-
tively regulates RhoA activity by stimulating GTP hydrolysis. Active RhoA and its downstream effectors 
are involved in the formation of actin stress fibers. Hypoxic regulation of ArhGAP29 is suggested; 
however, the molecular details how hypoxia regulates ArhGA29 expression remains to be elucidated 
(dashed arrow). 
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ArhGAP29 is a 142 kDa protein that was originally named PARG1 (PTPL1-associated 
RhoGAP 1) because of its association with the intracellular protein-tyrosine phosphatase 
(PTP) PTPL1 (Saras et al., 1997). ArhGAP29 is widely expressed in many cell types and 
tissues, most notably in heart and skeletal muscle (Saras et al., 1997). ArhGAP29 contains 
four domains: a N-terminal ZPH (ZK66.91a and PARG homology) region and a central cys-
teine rich region, which are responsible for protein-protein interactions, the Rho GTPase do-
main and a small C-terminal region that interacts with PTPL1 (Saras et al., 1997; Myagmar et 
al., 2005; Leslie et al., 2012). The transcriptional co-activator yes-associated protein (YAP), a 
negative regulator of the Hippo pathway, is reported to promote ArhGAP29 expression (Fig. 
6) (Qiao et al., 2017). Furthermore, hypoxia induces the expression of ArhGAP29 mRNA and 
protein as observed by J. Peters (laboratory of Prof. Katschinski). In contrast, the microRNA 
(miR)-1291 suppresses ArhGAP29 expression that is further involved in endometrial fibrosis 
(Xu et al., 2017). ArhGAP29 was identified as an effector of Ras-related GTPase Rap2 
(Meng et al., 2018). In addition, ArhGAP29 is mediated by the interaction with ras-interacting 
protein (Rasip) 1 and ras-association and dilute domain-containing protein (Radil), as an ef-
fector of the Ras-related GTPase Rap1 (Xu et al., 2011; Post et al., 2013). Through its asso-
ciation with Rap1 and Rap2, ArhGAP29 is involved in endothelial barrier function and vascu-
lar tubulogenesis (Xu et al., 2011; Post et al., 2013; Post et al., 2015; Barry et al., 2016). 
 
ArhGAP29 has a strong activity towards Rho and a weaker activity towards Rac1 and Cdc42 
(Saras et al., 1997; van Buul et al., 2014). Thus, it is not surprising that alterations in Arh-
GAP29 expression and activity result in changed RhoA/ROCK signalling, and modulation of 
actin cytoskeleton mediated cellular functions (refer to chapter 1.4.3). Endothelial cells defi-
cient in ArhGAP29 show increased RhoA/ROCK/myosin II activity resulting in a disorganised 
actin cytoskeleton, increased stress fiber formation, disturbed adhesions and a defected lu-
men formation (Xu et al., 2011). Consequently, ArhGAP29 influences many physiological 
and pathological events. For example, ArhGAP29 is known for its role in endothelial adhe-
sion, spreading and polarisation in vascular lumen formation as well as in endothelial tubu-
logenesis (Xu et al., 2011; Post et al., 2013; van Buul et al., 2014).  
 
In vivo studies on mice revealed a crucial role for ArhGAP29 to ensure embryonal develop-
ment, as knockout of ArhGAP29 in epiblasts cells and loss of function mutations result in 
embryonic lethality (Barry et al., 2016; Paul et al., 2017). A common birth defect, the nonsyn-
dromic cleft lip and / or palate (NSCL/P) is reported to correlate with several mutations of 
ArhGAP29 in humans (Leslie et al., 2012; Butali et al., 2014; Chandrasekharan and Rama-
nathan, 2014; Paul et al., 2017; Liu et al., 2017). The mutations of ArhGAP29 associated 
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with this congenital disability include functional non-coding variants, loss-of-function variants 
as well as point mutations (Savastano et al., 2017; Paul et al., 2017; Liu et al., 2017). 
Taken together, ArhGAP29 is involved in a wide range of cellular and developmental proc-
esses due to its regulatory role on RhoA signalling. Therefore, it can be hypothesised that 
ArhGAP29 expression needs to be carefully controlled to ensure precisely regulation of cy-
toskeletal-mediated cellular mechanisms. 
  
Introduction 
17 
1.5 Aims of this doctoral thesis 
Myofibroblasts play a crucial role in wound healing and tissue remodelling. However, dys-
functional myofibroblast differentiation results in pathological conditions, such as fibrosis and 
organ dysfunction. Myofibroblast differentiation underlies a highly orchestrated interplay of 
microenvironmental stimuli, such as mechanical tension, cytokine signalling and tissue oxy-
genation. The intricate molecular machinery regulating this process remains unclear. Rho 
GTPases, particularly the Rho family member RhoA, are known to be the main regulators of 
actin cytoskeleton remodelling. Rho activity also induces gene expression essential for the 
myofibroblast differentiation programme. The myofibroblast differentiation is mediated by 
MRTF-A/SRF signalling, one of the key inducers of the fibrotic response. 
 
Preliminary research by the laboratory of Prof. Katschinski revealed the hypoxic induction of 
the Rho GTPase activating protein ArhGAP29 in diverse cell types, including primary fibro-
blasts and ischemic cardiac tissue. Furthermore, J. Peters (laboratory of Prof. Katschinski) 
established a knockdown of ArhGAP29 in L929 cells, which resulted in changes in cell mor-
phology and actin cytoskeleton modulation. These findings suggest that ArhGAP29 is in-
volved in fine-tuning RhoA activity and MRTF/SRF signalling in hypoxia. Thus, analysing the 
function of ArhGAP29 in hypoxia would further the understanding of myofibroblast differentia-
tion and myofibroblast-related diseases, such as fibrosis. 
 
In this doctoral thesis, the impact of oxygenation on the myofibroblast differentiation pro-
gramme and the role of ArhGAP29 on the RhoA-MRTF-A/SRF signalling pathway in hypoxia 
were addressed through the following aims: 
1. To investigate the effect of hypoxia on the myofibroblast differentiation and contractile 
function in primary skin fibroblasts. 
2. To investigate the effect of hypoxia on RhoA activity. 
3. To analyse the role of ArhGAP29 on regulating RhoA activity and on remodelling of 
the actin cytoskeleton in hypoxia. 
4. To reveal the downstream effects of ArhGAP29 induction in hypoxia on MRTF-A/SRF 
signalling. 
5. To test if the knockdown of ArhGAP29 in primary fibroblasts has an impact on myofi-
broblast differentiation in hypoxia and if regulating ArhGAP29 expression could be a 
potential therapeutic strategy for treatment of ischemia-induced tissue remodelling.  
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2 Material and Methods 
2.1 Animals 
For primary cell isolation, 6-12 weeks old wildtype mice (Mus musculus, C57BL/6J) were 
purchased from Charles River, Germany or the central animal facility at the University 
Medical Center, Göttingen. Animals were kept according to animal welfare regulations.  
 
2.2 Cell lines 
Cell lines used for the experiments are described in Table 1. L929 cells were purchased from 
the American Type Culture Collection (ATCC, Manassas, VA, USA). C2C12 cells were pro-
vided by S. Rohrbach (Institute of Physiology, Justus Liebig University Giessen, Germany). 
All MEF cell lines were kindly provided by R.S. Johnson (Department of Physiology, Universi-
ty of Cambridge, U.K). 
Table 1: Cell lines 
Cell line Origin 
C2C12 murine myoblasts 
HEK293T human embryonic kidney cells  
L929 murine fibroblasts, connective tissue 
L929 ArhGAP29 kd murine fibroblasts, connective tissue 
ArhGAP29 knockdown (Vogler et al., 2013) 
L929 shHIF-1α murine fibroblasts, connective tissue 
HIF-1α knockdown (Vogler et al., 2013) 
L929 shco murine fibroblasts, connective tissue 
non-targeting shRNA control (Vogler et al., 
2013) 
MEF (MEF +/+) mouse embryonic fibroblasts (Ryan et al., 
2000) 
MEF HIF-1α-/- (MEF -/-) mouse embryonic fibroblasts derived from 
HIF-1α null embryos (Ryan et al., 2000) 
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2.3 Cell culture media and solutions 
Purchased cell culture medium, supplements and supplies are shown in Table 2.  
The components of different cell culture media and solutions used for experiments are indi-
cated in Table 3. 
Table 2: Cell culture medium, supplements and supplies 
Product Manufacturer Catalogue number 
DMEM, high glucose PANTM Biotech P04-03590 
DMEM / F12 (1:1) PANTM Biotech P04-41150 
Filtrated Bovine Serum (FBS 
Good) 
PANTM Biotech P40-37500 
Minimum Essential Medium 
Non-Essential Amino Acids 
(MEM-NEAA) 
PANTM Biotech P08-32100 
Opti-MEM® Gibco  31985-047 
Penicillin-Streptomycin PANTM Biotech P06-07100 
Trypsin/EDTA PANTM Biotech P10-023100 
 
Table 3: Cell culture medium components and solutions 
Medium / solution Ingredients 
DMEM culture medium DMEM, high glucose  
10% FBS, heat inactivated 
50 U/ml Penicillin 
50 µg/ml Streptomycin 
Primary skin fibroblast culture medium DMEM / F12 (1:1)  
10% FBS, heat inactivated 
1% MEM NEAA 
50 U/ml Penicillin 
50 µg/ml Streptomycin 
Starvation medium DMEM culture medium or primary fibroblast 
culture medium with supplements and re-
duced serum concentration (0.1% FBS, heat 
inactivated) 
Trypsin/EDTA solution 1 mM EDTA in Trypsin 
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2.4 Chemicals  
Chemicals used for the experiments are listed in Table 4. 
Table 4: Chemicals 
 Product Manufacturer Catalogue number 
2,3-Butanedione Monoxime 
(BDM) 
Cell Biolabs, Inc. 20105; CBA-201 
4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid 
(HEPES) 
PAN™ Biotech P05-01100 
4',6-diamidino-2-phenylindole 
(DAPI) 
Sigma-Aldrich D9542-10MG 
Acetic acid Carl Roth  3738.5 
Agar-agar Carl Roth  5210.2 
Agarose Broad Range Carl Roth  T846.3 
Albumine Bovine Fraction V 
(BSA) 
Applichem A1391.0500 
Ammonium persulfate (APS) Carl Roth 9592 
Ampicillin Sodium salt Carl Roth  K029.2 
β-Mercaptoethanol Carl Roth  4277.1 
Bromophenol blue sodium 
salt 
Carl Roth  A512.1 
Chloroform Carl Roth  3313.1 
Coumaric acid Sigma-Aldrich C-9008 
Dimethyloxalylglycine 
(DMOG) 
Enzo Biochem BML-E1347-0050 
Dimethyl sulfoxide (DMSO) Thermo Fisher Scientific F-515 
Di-Sodium hydrogen phos-
phate dihydrate 
(Na2HPO4 x 2 H2O) 
Carl Roth  4984.1 
Dithiothreitol (DTT) Carl Roth 6908.1 
Ethylenediaminetetraacetic 
acid (EDTA) 
Carl Roth  8043.2 
Ethanol Carl Roth  9065.4 
Fluoromount™ Aqueous 
Mounting Medium  
Sigma-Aldrich F4680 
Gene Ruler DNA ladder, 1kB Thermo Fisher Scientific SM0311 
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Glutathione SepharoseTM GE Healthcare 17-5132-01 
Glycerol Carl Roth  3783.2 
Glycine Carl Roth  3908.2 
Hexadimethrine bromide 
(Polybrene) 
Th. Geyer H9268 
Hydrogen peroxide (H2O2) Sigma-Aldrich H1009  
Isopropanol Carl Roth  6752.4 
Isopropyl-β-D-
thiogalactopyranoside (IPTG) 
Fermentas R0392 
Lenti-XTM Concentrator TaKaRa 631231 
Lipofectamine® 2000 Invitrogen 11668-019 
Luminol Carl Roth  4203.1 
Methanol Carl Roth  4627.5 
Monopotassium phosphate 
(KH2PO4) 
Carl Roth  6875.1 
Nonidet® P40 (NP-40) Sigma-Aldrich 74385-1L 
Paraformaldehyde Carl Roth  0335.1 
PageRuler™ Prestained Pro-
tein Ladder  
Thermo Fisher Scientific 221616 
Phenylmethane sulfonyl fluo-
ride (PMSF) 
Carl Roth 6367.1 
Protease Inhibitor Cocktail 
Tablet cOmpleteTM Mini, 
EDTA-free 
Roche 04693124001 
Protein Assay Dye Reagent 
Concentrate  
BioRad 500-0006 
Potassium chloride (KCl) Carl Roth  6787.1 
Ponceau Carl Roth  P7170 
Puromycin Gibco  A11138-03 
RNase-free water Thermo Fisher Scientific R0581 
Roentogen liquid, X-ray de-
veloper solution 
Tetenal 103482 
Roentogen Superfix, X-ray 
fixer solution 
Tetenal 103655 
Rotiphorese® Gel 30 Carl Roth  3029.2 
Roti Safe Gel Stain Carl Roth  3865.1 
Skim milk powder AppliChem A0830.0500 
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Sodium chloride (NaCl) Carl Roth  9265.2 
Sodium dodecyl sulfate 
(SDS) 
Carl Roth  4360.2 
Sodium fluoride (NaF) Sigma-Aldrich  87920-100G 
Sodium orthovanadate 
(Na3VO4) 
Sigma-Aldrich S508-50G 
Tetramethylethylenediamine 
(TEMED) 
Carl Roth  2367.3 
TGF-β1, human PeproTech 100-21C-10UG 
Tris(hydroxymethyl)-
aminomethane (TRIS) 
Carl Roth  5429.3 
Triton X-100 Carl Roth  3051.4 
TRIzol® Thermo Fisher Scientific 
(Ambion) 
15596018 
Tween® 20 Carl Roth  91271 
 
2.5 Buffers and solutions 
The components of buffers and solutions used for experiments are given in Table 5. 
Table 5: Buffers and solutions 
Buffer / solution Ingredients 
Immunofluorescence 
Blocking buffer  1% BSA in PBS 
Cell permeabilisation buffer 0.2% Triton X-100 in PBS 
DAPI staining solution 5 mg DAPI in 5 ml H2O 
Isolation of primary skin fibroblasts 
Digestion buffer 400 U/ml Collagenase II in primary fibroblast 
culture medium 
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Rho GTPase activity assay 
Bacterial lysis and washing buffer 
(STE-PMSF buffer) 
10 mM TRIS, pH 8.0 
150 mM NaCl 
1 mM EDTA 
1mM PMSF 
in ddH2O 
Cell lysis buffer 
 
25 mM HEPES, pH 7.5 
150 mM NaCL 
10 mM MgCl2 
1% NP-40 
1 mM EDTA  
10% Glycerol 
1x Mg2+ buffer 
 
5x Mg2+ buffer 
25 mM NaF 
1 mM Na3VO4 
100 µg PMSF 
10% Glycerol 
1 Protease Inhibitor Cocktail Tablet  
(per 10  ml buffer volume)  
5x Mg2+ buffer 
 
125 mM HEPES, pH 7.5 
750 mM NaCl 
5% NP-40 
50 mM MgCl2 
5 mM EDTA 
in ddH2O 
SDS-PAGE and Immunoblot 
Cell lysis buffer  400 mM NaCl  
1 mM EDTA  
10 mM TRIS/HCl pH 8.0  
0.1% Triton X-100 
1:10 Protease inhibitor mix 
Enhanced chemiluminescence solution (ECL) 100 mM TRIS/HCl, pH 8.5 
90 mM Coumaric acid 
250 mM Luminol 
0.009% H2O2 
Immunoblot blocking buffer 5% Skimmed milk powder in 1x PBS 
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Immunoblot transfer buffer 25 mM TRIS 
192 mM Glycine 
20% Methanol 
Sample loading buffer (6x Laemmli) 100 mM TRIS, pH 6.8 
4% SDS 
0.2% Bromophenol blue 
20% Glycerol 
5% β-mercaptoethanol 
Phosphate buffered saline (PBS) 137 mM NaCl  
2.7 mM KCl  
4.3 mM Na2HPO4 x 7H2O  
1.4 mM KH2PO4, pH 7.4  
Ponceau S staining solution 0.1% Ponceau 
5% Acetic acid 
Protease inhibitor mix 1 Protease Inhibitor Cocktail Tablet in 1.5 ml 
ddH2O 
5x SDS-PAGE running buffer  
 
125 mM TRIS 
1.25 M Glycine 
0.5% SDS 
in ddH2O, pH 8.3 
TBS-T (TRIS-buffered saline with Tween-20 
washing buffer) 
1 M TRIS, pH 7.6 
5 M NaCl 
10% Tween-20 
X-ray developer solution 1:3.5 Roentogen liquid in ddH2O 
X-ray fixing solution 1:2 Roentogen Superfix in ddH2O 
 
2.6 Enzymes 
Purchased enzymes are listed in Table 6. 
Table 6: Enzymes 
Enzyme Manufacturer Catalogue number 
Collagenase Type II Biochrom C2-22 
Lysozyme Sigma-Aldrich L6876-1G 
Rho Inhibitor I,  
C3 Transferase 
Cytoskeleton, Inc.  CT04 
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2.7 Kits 
Commercially available kits used for experiments are listed in Table 7. 
Table 7: Kits 
Kit Manufacturer Catalogue number 
Cell Contraction Assay  Cell Biolabs, Inc. CBA-201 
Dual-Luciferase® Reporter 
Assay System 
Promega E1910 
First Strand cDNA Synthesis  Thermo Fisher Scientific K1612 
SensiMixTM SYBR Lo-ROX 
Mix  
Bioline QT6525-05 
 
2.8 Antibodies  
Antibodies used for immunoblotting and immunostaining are listed in Tables 8 to 11. 
Table 8: Immunoblotting primary antibodies 
Antibody Origin Dilution Manufacturer Catalogue number 
anti-ArhGAP29 rabbit 1:2000 Novus NBP-05989 
anti-HIF-1α rabbit 1:1000 Novus NB100-449 
anti-RhoA rabbit 1:500 Cell Signaling 67B9 mAb#2117 
anti-Tubulin rabbit 1:1500 abcam ab6046 
anti-Vinculin  mouse 1:10000 Sigma-Aldrich V9264 
 
Table 9: Immunostaining primary antibody 
Antibody Origin Dilution Manufacturer Catalogue number 
anti-αSMA rabbit 1:500 Sigma-Aldrich A2547 
anti-MRTF-A rabbit 1:200 Kindly provided by Prof. G. Posern, Mar-
tin-Luther University, 
Halle-Wittenberg, Germany 
 
Table 10: Immunoblotting secondary antibodies 
Antibody Origin Dilution Manufacturer Catalogue number 
anti-mouse HRP goat 1:1000 Santa Cruz sc-2005 
anti-rabbit HRP goat 1:10000 Santa Cruz sc-2004 
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Table 11: Immunostaining secondary antibody 
Antibody Origin Dilution Manufacturer Catalogue number 
anti-mouse FITC goat 1:200 Sigma-Aldrich F0257 
anti-rabbit FITC goat 1:200 Sigma-Aldrich F0382 
 
2.9 Conjugated fluorescent probes 
For F-actin staining, the phallotoxin phalloidin probe conjugated to fluorescent Alexa FluorTM 
594 or Texas RedTM-X dye was used. Details are given in Table 12. 
Table 12: Conjugated fluorescent probe 
Probe Dilution Manufacturer Catalogue number 
Alexa FluorTM  594 
Phalloidin  
1:400 Thermo Fisher  
Scientific 
A12381 
Texas Red™-X 
Phalloidin 
1:400 Thermo Fisher  
Scientific 
T7471 
 
2.10 qRT-PCR specific oligonucleotides 
Primers in Table 13 were designed specifically for the templates of interests with Primer3 
and BLAST by NCBI for Mus musculus. Primers were purchased from Biomers. 
Table 13: qRT-PCR specific-oligonucleotides 
Gene Sequence (5’ – 3’) Annealing  
temperature 
αSMA fw GCCAGTCGCTGTCAGGAACCC 65°C 
rev GCCAGCCAAGTCCAGACGCA 
ArhGAP29 fw ATCTGAGGCGAGTGGTGGAT 58°C 
rev AGCAGCTTGGGGCTTTTACA 
CTGF fw GTGTGCACTGCCAAAGATGGT 58°C 
rev GTCCGGATGCACTTTTTGCC 
Ms12 fw GAAGCTGCCAAGGCCTTAGA 58°C 
rev AACTGCAACCAACCACCTTC 
PHD3 fw GGCCGCTGTATCACCTGTAT 58°C 
rev TTCTGCCCTTTCTTCAGCAT 
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2.11 Bacteria culture material and medium 
The medium for bacteria culture are listed in Table 14. 
Table 14: Bacteria culture material and medium 
Medium Ingredients Catalogue number 
LB-Agar (Luria/Miller) Carl Roth X969.2 
LB-Medium (Luria/Miller) Carl Roth X968.2 
 
2.12 Bacterial strains 
Following bacterial strains were used: E.coli Top 10 F- mcrA Δ(mrr-hsdRMS-mcrBC) 
f80lacZΔM15 ΔlacX74 deoR recA1 araD139 Δ(ara-leu)7697 galU galK rpsL endA1 nupG 
purchased from Invitrogen. In addition, BL21 was used to express pGEX-GST-RBD-
Rhotekin, which was kindly provided by Prof. A. J. Ridley, King´s College London, London, 
U.K. 
2.13 Plasmids 
Plasmids used for luciferase reporter gene activity, lentiviral packaging and genetic modifica-
tion and RhoA activity assay are listed in Table 15.  
Table 15: Plasmids 
Lu
ci
fe
ra
se
 a
c-
tiv
ity
 
Plasmid Origin 
pSRE.L Kindly provided by Dr. J. Mao and Dr D. Wu, 
University of Rochester, Rochester, NY, USA 
pRL.TK Promega 
Le
nt
iv
ira
l 
pa
ck
ag
in
g 
pLP1 Invitrogen (Thermo Fisher Scientific) 
pLP2 Invitrogen (Thermo Fisher Scientific) 
pLP-VSVG Invitrogen (Thermo Fisher Scientific) 
Ex
pr
es
si
on
  
ve
ct
or
 
MRTF-A-GFP Kindly provided by Prof. G. Posern,  
Martin-Luther University Halle-Wittenberg, Ger-
many 
pLKO.1-puro ArhGAP29-
shRNA,  TRCN0000023926 
Sigma-Aldrich 
pLKO.1-puro non-targeting 
shRNA, #SHC002 
Sigma-Aldrich 
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R
ho
A 
ac
tiv
ity
 pGEX-GST-RBD-Rhotekin Kindly provided by Prof. A. J. Ridley,  
King´s College London, London, U.K. 
2.14 Consumables 
All common laboratory consumables are listed in Table 16. 
Table 16: Consumables 
Product Type Manufacturer Catalogue number 
Cell culture flask 25 cm² Greiner Bio-One 690175 
75 cm² 658175 
Cell culture  
multiwell plate 
6-well Sarstedt 83.3920 
12-well 83.3921 
24-well 83.3922 
Cell culture dish 35 x 10 mm Sarstedt 83.3900.300 
60 x 15 mm 83.3901 
100 x 20 mm 83.3902.300 
150 x 20 mm 83.3903.300 
Cell strainer, 
EASYstrainerTM 
70 µm Greiner Bio-One 542070 
Chemilumines-
cence film, Am-
ersham Hyper-
filmTM ECL 
18 x 24 cm GE Healthcare 28906837 
Cover slips  20 x 20 mm Carl Roth H873.2 
CryoPure Tubes 1.8 ml Sarstedt 72.379 
Disposable filter  0.2 µm Th. Geyer 90491011 
Disposable 
scalpel 
No. 21 PFM Medical 02.011.30.021 
Glass Pasteur 
Pipette 
225 mm BRAND ISO 7712 
Microplates 96-well, clear Sarstedt 82.1581 
96-well, white Greiner Bio-One 655075 
Microscope 
Slides 
76 x 26 mm Th. Geyer 7695002 
Nitrocellulose 
Blotting Mem-
300 mm x 4 m, 0.45  
µm 
GE Healthcare 10600003 
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brane,  
AmershamTM 
ProtranTM 
PCR strips 8 x 0.2 ml Greiner Bio-One 673210 
PCR strip caps n.a. Greiner Bio-One 373250 
Petri dish 92 x 16 mm Sarstedt 82.1473.001 
Pipette tips  10 µl Sarstedt 70.1130 
200 µl 70.760.012 
1000 µl  70.762.010 
Reaction cups  0.5 ml Sarstedt 72.699 
1.5 ml 72.690.001 
2.5 ml 72.691 
Syringe, Luer-
LokTM Plasti-
pakTM 
60 ml BD Medical Technol-
ogy 
300865 
Syringe, Microli-
terTM Hamilton  
710 N Carl Roth X036.1 
Serological pi-
pettes  
5 ml Sarstedt 86.1253.001 
10 ml 86.1254.001 
25 ml 86.1685.001 
Tubes 15 ml Sarstedt 62.554.502 
50 ml 62.547.254 
 
2.15 Devices  
Laboratory devices for experiments are listed in Table 17. 
Table 17: Devices 
Application Device Manufacturer 
Cell counting Neubauer chamber Marienfeld 
Cell culture incubator CB159 Binder 
Cell freezing Mr. Frosty™ Nalgene 
Centrifugation Centrifuge 5415R Eppendorf 
Centrifuge 5810R Eppendorf 
Micro Centrifuge Carl Roth  
Electrophoresis chamber PerfectBlue Peqlab 
Fume hood n.a. Köttermann 
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Heating block BT2000  Kleinfeld Labortechnik 
Hypoxia workstation InvivO2 400 Baker Ruskinn 
Imaging IX83, inverted fluorescence 
microscope 
Olympus 
Axiovert 200 M,  
fluorescence microscope 
Zeiss 
LSM 510-META, confocal 
laser scanning microscope 
Zeiss 
Immunoblotting Transfer PerfectBlue Semi-Dry 
Electroblotter 
Peqlab 
Laminar flow hood Hera Safe K12 Thermo Electron 
Luminometer Centro LB 960 Berthold Technologies 
Magnetic stirrer Ikamag®RH IKA Labortech 
Microplate reader Centro LB 960  Berthold Technologies 
Mixer Vortex-Genie 2  Scientific Industries 
PCR cycler Primus 96 Thermocycler Peqlab 
Pipette filler Pipetus® Hirschmann 
Real-Time PCR cycler Mx3000P Strategene 
Scale AC 2115 Satorius 
Shaker Minitron INFORNS HAT AG 
Spectrophotometer NanoDrop 2000c Thermo Fisher Scientific 
Water bath Störktronic W22 Medigen 
 
2.16 Software  
Software used for analysing the data is given in Table 18. Figure 2, 5 and 6 were created 
with BioRender (https://biorender.com/). 
Table 18: Software 
Product Version Manufacturer 
Adobe Photoshop CS2 9.0 Adobe Systems 
Citavi 6.3 Swiss Academic Software  
CorelDRAW® X5 15.2.0.661 Corel Corporation 
GraphPad PRISM 5 5.01 GraphPad Software 
Image J 1.51g Wayne Rasband 
Microsoft Office Excel 2016 Microsoft 
Microsoft Office Word 2016 Microsoft 
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MxPro Mx3005P V4.10 Agilent Technologies 
NanoDrop 2000 software 1.5 Thermo Fisher Scientific 
 
2.17 Cell biological methods 
2.17.1 Cell Cultivation 
Cell lines (C2C12, MEF and L929) were cultured in DMEM high glucose medium supple-
mented with 10% FBS and 1% P/S (Tab. 3). Primary skin fibroblasts were cultured in 
DMEM/F12 (1:1) medium supplemented with 10% FBS, 1% P/S and 1% MEM-NEAA (Tab. 
3). In general, cells were cultured under normoxic conditions (20% O2) in a humidified incu-
bator with 5% CO2 at 37°C. For hypoxic experiments, cells were incubated in a humidified 
hypoxia working station (Ruskinn) with a reduced oxygen supply of 1%  O2, 5% CO2 and 
37°C. In order to maintain the knockdown of ArhGAP29 and HIF-1α in L929 cells, the me-
dium was constantly enriched with 20 µg/ml puromycin. The L929 non-targeting shRNA con-
trol cells (shC) were treated with the same amount of puromycin for constant selection. 
 
2.17.2 Isolation and cultivation of murine primary skin fibroblasts 
Primary skin fibroblasts (PSF) were isolated from murine tail tissue. Therefore, mice were 
sacrificed by CO2 inhalation followed by cervical dislocation. Ethanol sterilised tails were re-
moved with a sterile scalpel and washed in 70% EtOH for 10 min. The removal of tails was 
followed by an incubation of the tails in primary fibroblast culture medium (Tab. 3) on ice for 
1 h. Next, tails were briefly washed in 1x PBS supplemented with 2% P/S and with 70% 
EtOH for 10 min. After the washing steps, tails were minced using a sterile scalpel and di-
gested by 400 U/ml Collagenase Type II (Tab. 6) at 37 °C overnight under constant stirring. 
The digested tissue was filtered through a 70 µm nylon cell strainer and centrifuged for 5 min 
at 200 x g. The cell pellet was gently resuspended in primary fibroblast culture medium (Tab. 
3). Next, the cell suspension was plated on a 75 cm² cell culture flask. To remove non-
fibroblasts and cell debris, the medium was removed after 24 h and adherent cells were 
washed three times with 1x PBS. Fresh fibroblast media was added, and cells were cultured 
under normal cell culture conditions (2.17.1). 
 
2.17.3 Cell contraction assay 
Three-dimensional collagen matrices were used to measure contractile forces of primary skin 
fibroblasts. The collagen-based cell contraction assay was performed following the manufac-
turer´s guidelines (Cell Biolabs). In short, cells were detached from the cell culture plates 
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using Trypsin/EDTA solution (Tab. 3) and resuspended in primary fibroblast medium. Colla-
gen lattice was prepared by mixing 100 µl of cell suspension containing a final concentration 
of 5 x 106 cells/ml and 400 µl of collagen gel working solution. Next, 0.5 ml of the cell-
collagen mix was added in a well of a 24-well plate and incubated for 1 h at 37°C. Fibroblast 
culture medium was added after polymerisation of the collagen gel. The cell-collagen gels 
were incubated under normal cell culture conditions for one day, followed by an additional 24 
h of normoxic (20% O2) or hypoxic (1% O2) incubation respectively. Contracting cells cause 
mechanical tension in the polymerised collagen matrix. Releasing the attached collagen ma-
trix from the sides of the culture dish with a sterile spatula results in mechanical unloading 
and contraction of the gel. As a control, cells were treated with 2,3-Butanedione Monoxime 
(BDM), a contraction inhibitor, 30 min before releasing the gel. To document the collagen gel 
size change, pictures were taken using an 8 MP cell phone camera. The collagen gel size 
change, determined as collagen area to well area ratio, was quantified using ImageJ soft-
ware. 
 
2.17.4 Lipid-based transfection 
Lipid-based transfection of cells was performed by using LipofectamineTM 2000 according to 
the manufacturer’s instructions (Invitrogen/Thermo Fisher Scientific). For the transfection 
procedure, 2 x 104 cells/ml were plated in a well of a 24-well plate. Thirty minutes prior trans-
fection, medium was replaced with antibiotic-free medium. The plasmid of interest was added 
to 50 µl Opti-MEM. Furthermore, 2 µl of LiptofectamineTM 2000 was diluted in 50 µl of Opti-
MEM and incubated for 5 min at RT. LiptofectamineTM 2000 mix and plasmid mix were com-
bined and incubated for 20 min at RT. Cells were transfected with 100 µl of the complexes 
per well. After 24 h incubation, media was replaced with fresh media containing 1% P/S. 
Transfected cells were cultured according to further experimental setups.  
 
2.17.5 Production of lentiviral particles 
Knockdown of ArhGAP29 in primary skin fibroblasts was generated by lentiviral delivery of 
shRNA. Non-targeting shRNA was used as a control. Lentiviral particles were produced in 
human embryonic kidney cells (HEK293T). For this purpose, a total number of 7x106 
HEK293T cells was seeded on a 75 cm² cell culture flask and cultured in antibiotic-free 
DMEM supplemented with 10% FBS until cells were confluent. The medium was exchanged 
with Opti-MEM® supplemented with 10% FBS. A transfection mix containing packaging 
plasmids and either a plasmid targeting the ArhGAP29 gene or a non-targeting RNA control 
(shRNA, Tab. 15) was prepared in serum-free Opti-MEM® as shown in Table 19. Following 
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an incubation of 5 min at RT, LipofectamineTM 2000 mix (36 µl LipofectamineTM 2000 in se-
rum-free Opti-MEM®, total volume 1.5 ml) was added to the transfection mix and blended 
gently. After an incubation of 20 min at RT, the transfection mix was carefully added to the 
HEK293T cells. The medium was replaced with antibiotic-free DMEM supplemented with 
10% FBS after 24 h.  
Lentiviral particle-containing supernatant was harvested 48 h after transfection. Optional, 
fresh antibiotic-free DMEM supplemented with 10% FBS was added to the cells for an addi-
tional harvest of lentiviral particle-containing supernatant after 24 h. In any case, lentiviral 
particles were purified and concentrated using Lenti-XTM concentrator according to the manu-
facturer´s protocol (Clontech) immediately. In brief, the supernatant was centrifuged at 2,000 
x g for 15 min at 4°C to remove cell debris. Next, the supernatant was transferred into a new 
tube and Lenti-XTM concentrator was added in a proportion rate of 1:3 to the total volume of 
supernatant. After incubation at 4°C for 45 min, the lentiviral particle-containing supernatant 
was centrifuged at 500 x g at 4°C for 45 min. The resulting viral particle-containing pellet was 
resuspended in 2 ml DMEM medium supplemented with 10% FBS and 1% P/S. Virus con-
taining suspension was stored at -80°C until transduction experiments. 
 
Table 19: Lentiviral transfection mix 
Plasmid Amount [µg] 
pLP1 4.2 
pLP2 2 
pLP-VSVG 2.8 
pLKO.1-puro targeting ArhGAP29  
or non-targeting control 
3 
Diluted in a total volume of 1.5 ml serum-free Opti-MEM®. 
 
2.17.6 Lentiviral transduction 
Lentiviral delivery of shRNA targeting ArhGAP29 was performed in primary skin fibroblasts in 
order to induce a genetic knockdown of ArhGAP29. 
After successful isolation of primary skin fibroblasts (2.17.2), cells were detached from the 
cell culture plate surface using enzymatic active Trypsin/EDTA solution for 5 min at 37°C. 
The process was stopped by adding primary fibroblast culture medium. The cell suspension 
was collected and gently spun down at 200 x g and 4°C. The cell pellet was suspended in 
primary fibroblast medium and equally distributed on a 6-well plate. As soon as the cells 
reached 50% confluency, lentiviral transduction was initiated. For this purpose, lentiviral par-
ticle-containing supernatant (2.17.5) was thawed. Next, 1 ml of lentiviral supernatant of the 
respective condition (ArhGAP29 targeting or non-targeting shRNA control) and 1 ml of pri-
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mary fibroblast medium was added to each well and mixed gently. To improve the lentiviral 
transduction rate, 8 µg/ml hexadimethrine bromide (polybrene) were added. Cells were incu-
bated for 48 h under normal cell culture conditions (2.17.1). 
Cells were washed with primary fibroblast medium and selected with 7µg/ml puromycin for 
24 h. Non-transduced, dead cells were removed by several washing steps with primary fibro-
blast medium. Fresh medium was added to successfully selected transduced cells. Cells 
were maintained and expanded according to the required experimental setup. ArhGAP29 
knockdown was verified by qRT-PCR analysis (2.20.3). In each experiment, besides a non-
targeting shRNA control, a non-transduced control was maintained as well. Each condition 
was performed in duplicates.  
 
2.17.7  Luciferase reporter gene assay 
For reporter gene analysis 90-95% confluent L929 cells were transfected with 1 µg of pSRE-
L and pRL-TK plasmid per well of a 24-well plate using LipofectaminTM 2000 according to the 
manufacturer’s guidelines. Transfections and untreated controls were performed in tripli-
cates. Cells were either introduced to hypoxic conditions 24 h after transfection or were kept 
under normoxic conditions as a control. For reporter gene analysis, cells were lysed 48 h 
after transfection in normoxic, and after 24 h in hypoxic culture conditions respectively.  
Activity of Firefly luciferase and Renilla luciferase was measured by using the Dual-
Luciferase Reporter Assay System (Promega) according to the manufacturer´s protocol. In 
short, medium was removed and cells were washed with 1x  PBS followed by cell lysis with 
50 µl of the provided 1x passive lysis buffer (PLB). Cell lysates were gently rocked for 15 min 
at RT and stored at -20°C for 24 h before the Luciferase activity was determined. For 
luciferase activity measurements, cell lysates were thawed on ice, 10 µl of the lysate were 
transferred to luminometer suitable 96-well multiplate containing 10 µl of lyophilised 
Luciferase Assay Reagent II (LAR II). Firefly activity was detected by a microplate luminome-
ter. Renilla firefly activity was initiated by adding 10 µl of STOP & GLO® reagent and quanti-
fied by a microplate luminometer. Detected Firefly luciferase activity was then normalised to 
Renilla intensity. Minor variations of the given protocol included freezing of the cell lysates 
and a reduced amount of cell lysate and of certain reagents are mentioned for PLB, LAR  II, 
STOP&GLO. 
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2.18 Histological methods 
2.18.1  Immunocytochemistry 
In order to visualise the location of specific proteins in cells, immunofluorescence staining 
was performed. In brief, cells were cultured on coverslips, washed with PBS and fixed with 
4% PFA for 15 min at RT. For permeabilisation, cells were washed and incubated in 0.2% 
Triton X-100/PBS for 15 min. Next, blocking buffer (1% BSA/PBS) was added for 5 min at 
RT. After blocking, primary antibody diluted in PBS was added (Tab. 9). Samples were kept 
in a wet chamber at RT for 2 h to allow the primary antibody to bind to its antigen. Following 
three washing steps with PBS, a fluorophore-coupled secondary antibody (Tab. 11) diluted in 
PBS or a conjugated fluorescent phalloidin probe (was added and incubated for 1 h in a wet 
chamber in the dark at RT. After washing three times with PBS, nuclei were stained with 
DAPI for 5 min at RT in the dark. After three additional washing steps with PBS, cells were 
mounted with FluoromountTM. Analyses were performed using different microscope setups 
(Tab. 17). Images were processed further with ImageJ and Adobe Photoshop CS2. 
 
2.18.2 Quantification of actin clusters  
To quantify F-actin clusters in cells, MiToBo Actin Analyzer 2D plugin 
(http://mitobo.informatik.uni-halle.de/index.php/Applications/ActinAnalyzer2D) (Möller et al., 
2016) was used in ImageJ. 
 
2.19 Protein biochemical methods  
2.19.1 Protein extraction 
For protein extraction, cells were washed twice with PBS, and excess liquid was discarded. 
Cells were lysed in ice cold lysis buffer and scraped off the cell culture dish. Homogenised 
cell lysates were transferred to pre-chilled reaction cups and shortly incubated on ice. Hypox-
ic samples were collected within the hypoxia workstation. Following a gentle mix of the cell 
lysates, samples were centrifuged at 13,000 x g for 10  min at 4°C. The protein containing 
supernatant was collected and transferred to a pre-chilled reaction cup. Protein concentration 
was determined by Bradford assay. Cell lysates were stored at -80°C unless directly pro-
cessed for SDS-PAGE (4.19.3). 
  
Material and Methods 
36 
2.19.2 Bradford assay 
Bradford assay was used to determine the protein concentration of cell lysates. Therefore, 
1 µl of the cell lysate was mixed with 200 µl 1:5 Protein Assay Dye Reagent Concentrate in a 
96-well plate. To calculate total protein concentration, the absorbance at 595 nm was meas-
ured with a microplate reader and compared to a BSA standard curve (range from 0.5 µg/µl 
to 4 µg/µl). 
 
2.19.3 SDS-PAGE  
Protein samples were separated according to their molecular weight by using the electric 
field of the sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). The 
system consists of two gels, the stacking gel (5%) and the resolving gel (6% or 10%) as rep-
resented in Table 20. If not shown differently, 10% resolving gels were used to detect HIF-1α 
protein, whereas 6% resolving gels were used to separate and detected ArhGAP29. For 
RhoA activity assays, 12% resolving gels were used. 
 
Cell lysates were mixed with 6x Laemmli loading buffer containing SDS and β-
mercaptoethanol, which leads to protein denaturation by breaking up non-covalent bonds. 
Samples were loaded into the polyacrylamide gel and ran at 40 mA to 50 mA. The PageRul-
erTM Prestained Protein Ladder was used for protein size determination. 
Table 20: Composition of stacking and resolving gel 
Component Stacking gel 
[ml] 
Resolving gel 
[ml] 
5% 6% 10% 12% 
ddH2O 6.8 15.9 11.9 9.9 
30% acrylamide mix 1.7 6 10 12 
1,5 M TRIS/HCl (pH 8,8) - 7.5 7.5 7.5 
1,0 M TRIS/HCl (pH 6,8) 1.25 - - - 
10% SDS 0.1 0.3 0.3 0.3 
10% ammonium persulfate 0.1 0.3 0.3 0.3 
TEMED 0.01 0.024 0.012 0.012 
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2.19.4 Immunoblot (Western Blot) 
Following the protein separation by SDS-PAGE (2.19.3), proteins were transferred onto a 
nitrocellulose membrane by using a semi-dry immunoblotting technique to visualise and ana-
lyse them. In short, the gel, nitrocellulose membrane and filter paper were soaked in im-
munoblot transfer buffer (25 mM TRIS,192 mM glycine, 20% methanol), before stacking 
them in the following order: a layer of three filter papers, nitrocellulose membrane, gel and 
another layer of 3 filter papers. The transfer was performed using the peqlab PerfectBlueTM 
Semi-Dry Electroblotter running at 2 mA/cm2 (280 mA, 30 V) for 1 h. The semi-dry im-
munoblotting technique uses an electric field, allowing negatively charged proteins to be 
transferred to the nitrocellulose membrane due to the attraction of a positive anode.  
To visualise successfully transferred proteins, the nitrocellulose membrane was stained with 
Ponceau S staining solution. Afterwards, the nitrocellulose membrane was washed with PBS 
to remove the Ponceau S staining and incubated in 5% skim milk powder dissolved in PBS 
for 1 h at RT to prevent unspecific antibody binding by blocking the membrane. Primary anti-
body was diluted in 5% skim milk powder / PBS according to table 8 and added to the nitro-
cellulose membrane overnight at 4°C. After incubation with primary antibody, the membrane 
was washed three times with PBS or TBS-T for 10 min at RT. HRP-coupled secondary anti-
body diluted in 5% skim milk powder/PBS was added for 1 h at RT. Finally, the membrane 
was washed three times for 10 min in PBS at RT. The membrane was incubated in ECL so-
lution for 1 min. For visualisation of the proteins, the membrane was exposed to chemilumi-
nescence sensitive films. 
 
2.19.5 Rho GTPase activity assay 
To detect active RhoA, a specific pulldown assay using the protein interaction with the Rho 
GTPase binding domain (RBD) from Rhotekin was performed.  
 
2.19.5.1 Production of GST-RBD proteins 
Glutathione-S-transferase-Rho binding domain of Rhotekin (GST-RBD) protein plasmids tak-
en from glycerol stocks (BL21 pGEX-GST-RBD-Rhotekin) were inoculated in 100  ml 100 
µg/ml AMP-containing LB medium at 37°C overnight under shaking conditions. The culture 
was diluted 1:20 in fresh 500 ml LB medium supplemented with 100 µg/ml AMP and incubat-
ed for 2 to 3 h at 37°C under shaking conditions. To induce the expression of the GST-RBD 
protein, 0.5 mM IPTG was added at 30°C for 2 h. The supernatant was spun down at 2,000 x 
g for 15 min. Pelleted bacteria was stored at -80 °C until further usage. 
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2.19.5.2 Production of GST-RBD protein beads 
Pelleted bacteria were lysed in 4 ml ice-cold lysis buffer (STE-PMSF) to recover GST-RBD 
protein. The pellet was homogenised using a 19G needle. To digest bacterial membranes, 
100 µg/ml lysozyme dissolved in 500 µl ice-cold lysis buffer (STE-PMSF) was added and 
incubated on ice for 15 min. Next, 5 mM DTT was added and gently mixed, followed by 1% 
Tween®-20 and 0.03% SDS. The total volume of the solution was equally distributed to 5 
reaction cups before centrifuged at 14,000 x g at 4°C for 30 min. The GST-RBD protein-
containing supernatant was collected. 
 
Before the Glutathione SepharoseTM beads were added to the supernatant, they had to be 
washed carefully. Therefore, 30 µl Glutathione SepharoseTM beads per condition were 
washed twice with STE-PMSF buffer and spun down gently for 1 min at 500 x g. Glutathione 
SepharoseTM beads were resuspended in 200 µl STE-PMSF buffer and added to GST-RBD 
protein supernatant, which was then incubated for 2 h at 4°C under end-to-end rotation. 
GST-RBD protein beads were washed with 500 µl 1x Mg2+ buffer and were centrifuged at 500 
x g for 1 min. The supernatant was discarded and beads were resuspended and stored in 
250 µl 1x Mg2+ buffer.  
 
2.19.5.3 Rho GTPase pulldown 
Cells were washed twice with ice-cold PBS, and lysed in 1x Mg2+ buffer. Cells were scraped 
from the cell culture plate, and the lysates were transferred into pre-chilled reaction tubes. 
Cell lysates were centrifuged at 14,000 x g at 4°C for 5 min. Supernatants were collected and 
transferred to new cold reaction tubes.  
To analyse the total RhoA amount, 40 µl of the cell lysate supernatant was kept separately. 
Lysates were incubated with 40 µl of GST-RBD protein beads per condition and incubated 
for 1.5 h to 2 h at 4°C under constant rotation. To pulldown the GST-RBD protein beads, 
lysates were centrifuged gently at 500 x g for 1 min. Active Rho-GST was bound to the 
beads. The beads were washed three times with 1x Mg2+ buffer and centrifuged at 500 x g at 
4°C for 2 min. Sample buffer (35 µl 6x Laemmli) was mixed with 1M DTT (1:5) and added to 
the samples. Samples were boiled at 95 °C for 5 min afterwards. Immunoblotting was per-
formed to analyse the active GST-RBD protein and compare it to the whole cell lysates, 
which were stored previously. 
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2.20 Molecular biological methods 
2.20.1 RNA isolation 
RNA was isolated according to manufacturer’s guidelines using the TRIzol® reagent. In short, 
cells were washed twice with PBS and lysed in 0.5 ml TRIzol® reagent. Homogenised cell 
lysates were transferred into reaction tubes and mixed with 100 µl chloroform by gently in-
verting the tubes for several seconds. After 2 min incubation at RT, lysates were centrifuged 
at 12,000 x g for 15 min at 4 °C to separate RNA from proteins. After centrifugation, the 
aqueous RNA-containing phase was transferred in a new reaction tube and mixed with 250 
µl isopropanol. In order to precipitate the RNA, samples were incubated at -20 °C for 20 min 
up to 1 h. After the incubation, samples were mixed again and spun down at 12,000 x g for 
20 min at 4°C. The supernatant was removed and the RNA pellet was washed in 0.5 ml 75% 
EtOH followed by a centrifugation step at 12,000 x g for 10 min at 4°C. After washing, the 
RNA pellet was air dried at RT and resuspended in 11 µl nuclease-free water. Samples were 
incubated at 56 °C for 10 min to dissolve the RNA pellet. A spectrophotometer (NanoDrop 
200c) was used to determine the RNA concentration. Isolated RNA was stored at -80°C if not 
used immediately. 
 
2.20.2 cDNA synthesis 
Isolated RNA was transcribed into complementary DNA (cDNA) using the Fermentas First 
Strand cDNA Synthesis kit according to manufacturer’s guidelines. Briefly, 1 µg to 1.5 µg of 
isolated RNA was transcribed into cDNA. Template RNA was incubated with oligo dT primers 
at 65°C for 10 min. For cDNA synthesis, the reaction mix (Tab. 21) was added and the sam-
ples were incubated at 37°C for 60 min. To stop enzymatic activity, samples were incubated 
at 70 °C for 10 min. The cDNA was stored at -20°C upon further usage. 
Table 21: cDNA synthesis reaction mix (1x) 
Reagent Volume [µl] 
M-MLV Reverse Transcriptase 2 
RiboLock RNase Inhibitor 1 
dNTP Mix 2 
5x Reaction Buffer 4 
Total Volume 9 
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2.20.3  Quantitative real-time PCR (qRT-PCR) 
To quantify and compare gene expression, quantitative real-time polymerase chain reaction 
(qRT-PCR) was used. cDNA was amplified with specific exon spanning oligonucleotides. 
SensiMixTM SYBR® Low-ROX kit was used for intercalation of SYBR green fluorescent dye 
with double-stranded DNA. ROX (5-carboxy-X-rhodamine) is an optional reference fluores-
cent dye, which was not considered in this experimental setup. Amplification was detected by 
Agilent Mx3005P light cycler. As transcript abundance correlates with fluorescence intensity, 
it was possible to quantify gene expression levels by fluorescence measurement.  
qRT-PCR method was performed according to the manufacturer’s instructions (Bioline) using 
the PCR reaction mix shown in Table 22. 
Table 22: qRT-PCR reaction mix (1x) 
Reagent Volume [µl]  
SensiMixTM SYBR® Low-ROX kit 12.5 
Primer fw 0.5 
Primer rev 0.5 
cDNA 1 
H2O 10.5 
Total volume 25 
 
qRT-PCR was performed in Agilent Mx3005P light cycler using following cycling programme 
(Tab. 23) adapted to the gene´s specific primer (Tab. 13) annealing temperatures TM . 
Table 23: qRT-PCR cycling programme 
Stage Temperature [°C] Time [min] Cycles 
Initial activation 95 10:00 1 
Denaturation 95 00:15  
40 Annealing TM 00:20 
Elongation 72 00:30 
Dissociation  95 1:00  
1 TM 00:30 
95 00:30 
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To analyse gene expression levels, the MxPro software and the comparative ΔΔCT method 
was used. The target gene expression was normalised to the unaltered, endogenous refer-
ence gene (murine ribosomal protein S12, ms12; housekeeping gene). The CT value repre-
sents the amount of PCR cycles after which a sample´s fluorescent signal was detectable 
exceeding the threshold (fluorescent background).  
ΔCT values result from the calculated differences between the housekeeping gene CT-values 
and the gene of interest CT-values (ΔCT= CT gene of interest - CT housekeeping gene). The 
mean value of control samples (i.e. normoxic, wildtype control) was calculated and subtract-
ed from the experimental samples (i.e. hypoxic incubation) ΔCT values to normalise them, 
resulting in ΔΔCT. In order to calculate the relative expression fold change, the ΔΔCT values 
have to be inserted in the formula 2-ΔΔCT. 
 
2.21 Statistics 
For statistic analysis and graphic presentation of data sets, GraphPad Prism 5 software was 
used. To determine statistic outliers, Grubb´s test was performed using the freely available 
online software provided by GraphPad (https://www.graphpad.com/quickcalcs/Grubbs1.cfm). 
Data were analysed by unpaired 2-tailed Student´s t-test. Analysed data are presented with 
error bars indicating standard error of the mean (± SEM). Statistic significance was set with a 
p- value < 0.05. Analysed sample size is represented in each experiment figure respectively. 
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3 Results 
3.1 Hypoxia impairs myofibroblast differentiation and contractile function 
3.1.1 The myofibroblast markers α smooth muscle actin and transgelin are de-
creased in hypoxia 
To investigate the effect of reduced oxygenation on the myofibroblast differentiation, murine 
PSF cultured under standard normoxic conditions (20% O2, 24 h) were exposed to hypoxia 
(1% O2) for 4 h and 24 h. Myofibroblasts differ from fibroblasts in de novo expression of 
αSMA (Hinz, 2007). Since the most common marker for activated myofibroblasts is αSMA, it 
was used in this study to distinguish myofibroblasts from fibroblasts. 
 
Under normoxic culture conditions, mRNA expression levels of αSMA increased constantly 
over time (4 to 28 h after plating). Prolonged normoxic incubation (48 h after plating) resulted 
in a negligible decrease of αSMA. Notably, after 24 h in hypoxia, mRNA expression of αSMA 
decreased significantly in the analysed PSF compared to the normoxic controls (Fig. 7A). 
Immunofluorescence stainings of PSF furthermore demonstrated that fewer cells expressed 
the myofibroblast marker αSMA colocalised with actin stress fibers in hypoxia in contrast to 
normoxia (Fig. 7C). These findings were verified by counting αSMA-positive fibroblasts in 
which αSMA colocalised with phalloidin stained F-actin (Fig. 7D).  
Besides αSMA, transgelin (Tagln) has been reported to be a marker for myofibroblasts 
(Scharenberg et al., 2014; Dolivo et al., 2017). The Tagln expression profile was found to be 
similar to the αSMA expression in PSF. In normoxia, Tagln was increased within 4 to 24 h 
after plating of the cells. Prolonged normoxia resulted in a slight decrease in Tagln expres-
sion. However, the expression of Tagln in hypoxia was significantly reduced after 24 h com-
pared to the normoxic samples after 48 h (Fig. 7B).  
 
Taken together, plating PSF on a regular cell culture dish under standard normoxic cell cul-
ture conditions resulted in the differentiation of fibroblasts to myofibroblasts. This finding was 
demonstrated by increased expression of the myofibroblast markers αSMA and Tagln. In 
contrast, hypoxia impaired the myofibroblast differentiation as shown by reduced expression 
of αSMA and Tagln.  
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Figure 7: Hypoxia impairs fibroblast to myofibroblast differentiation. Primary skin fibroblasts 
were cultured in normoxia (20% O2) or exposed to hypoxia (1% O2) for the indicated time points. The 
mRNA expression of the myofibroblast specific markers αSMA (A) and Tagln (B) were analysed by 
qRT-PCR. In (A) and (B) three to four samples per condition were analysed. The mRNA expression 
levels were normalised to the housekeeping gene ms12 and are shown as fold change compared to 
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normoxia (20% O2, 4h). Hypoxia resulted in a significant decrease of αSMA and Tagln. (C) Cells were 
analysed by immunofluorescence and Alexa FluorTM 594 conjugated phalloidin staining for αSMA and 
F-actin. Arrows indicate colocalisation of αSMA with F-actin, identifying αSMA-positive cells. Hypoxia 
resulted in a reduction of αSMA-positive cells. (D) Cells in which αSMA colocalises with F-actin were 
counted and quantified as percentage of total cell number. For each condition, at least 200 cells were 
analysed. Error bars represent mean ± SEM, p= ≤0.05. 
 
3.1.2 The stimulating effect of transforming growth factor-β on the myofibroblast 
differentiation is blunted in hypoxia 
The cytokine TGF-β plays a significant role in the fibroblast to myofibroblast differentiation 
process (Midgley et al., 2013). To stimulate the fibroblast to myofibroblast differentiation, 
PSF were treated with TGF-β. The cytokine was added to the cells after 24 h of normoxic 
incubation and one hour prior to the exposure to hypoxia. Two different concentrations (2 
ng/ml and 10 ng/ml) of TGF-β were applied. Treatment with TGF-β further stimulated the 
myofibroblast differentiation in normoxia compared to the untreated control, as shown in a 
significant increase of αSMA mRNA expression. However, the activating effect of TGF-β on 
the myofibroblast differentiation was blunted in hypoxia (Fig. 8A). Similar results were ob-
served for the expression of Tagln in which a TGF-β concentration of 10 ng/ml resulted in a 
significant increase of Tagln mRNA expression. This stimulating effect of TGF-β was reduced 
in hypoxia (Fig. 8B).  
 
 
Figure 8: Hypoxia diminishes the stimulating effect of TGF-β on the myofibroblast differentia-
tion. Primary skin fibroblasts were treated with the indicated concentrations of TGF-β and incubated in 
normoxia (20%  O2) or hypoxia (1% O2) for 24 h. The mRNA expression of the myofibroblast specific 
markers αSMA (A) and Tagln (B) were analysed by qRT-PCR. The mRNA expression levels were 
normalised to the housekeeping gene ms12 and are shown as fold change compared to the untreated 
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normoxic control. Four samples per condition were analysed. The stimulating effect of TGF-β on the 
fibroblast to myofibroblast differentiation in normoxia was found to be blunted in hypoxia as shown in 
reduced expression of the myofibroblast markers αSMA and Tagln. Error bars represent mean ± SEM, 
p= ≤0.05. 
 
3.1.3 The ability of primary fibroblasts to develop contractile forces is diminished in 
hypoxia 
One critical role of myofibroblasts in the wound healing process is the ability to close wounds 
due to their contractile characteristics (Li and Wang, 2009). 
To investigate the ability for contraction, PSF were mixed in three-dimensional collagen ma-
trices and cultured in normoxia. After 24 h in normoxia, some samples were incubated in 
hypoxia for 24 h. Mechanical tension in the polymerised collagen matrix is caused by con-
tracting cells. To measure contractile forces, the collagen lattice was released, which re-
sulted in mechanical unloading and shrinkage of the collagen gel. The change of the gel size 
was analysed by measuring the ratio of collagen area to well area (Fig. 9). In normoxia, the 
cells developed more contractile forces compared to hypoxia. This resulted in a significantly 
smaller collagen matrix in the normoxic samples compared to the hypoxic samples. As a 
control condition, cells were treated with BDM, a myosin ATPase inhibitor, which hinders 
contraction (Soeno et al., 1999). Upon treatment with the contraction inhibitor BDM, the col-
lagen gel size did not significantly change over time corresponding to less contractile forces.  
 
 
Figure 9: Hypoxia affects the contraction ability of myofibroblasts. (A) Primary skin fibroblasts 
were plated on collagen matrices and were incubated in normoxia (20% O2) or hypoxia (1% O2). 
Change of the gel size after release was determined by quantifying the collagen area to well area ra-
tio. The graph shows n=4 collagen gels per condition. Error bars represent mean ± SEM, p= ≤0.05. (B) 
0 8 
1%
 O
2
20
%
 O
2
20
%
 
+ 
2,
 3
-B
D
M
O
2
 
24 
120
100
80
60
40
20
0
0 8 16 24 time [h] time [h]
co
lla
ge
n 
ar
ea
 / 
w
el
l a
re
a 
[%
]
*
*
*
Results 
46 
Images show the representative collagen gels which were documented 0, 8 and 24 h after release. 
Cells isolated from at least four different animals were pooled. In normoxia, the gel size was reduced, 
indicating a contractile function of the cells. This effect was less distinct in hypoxic samples or under 
treatment with contraction inhibitor 2, 3-Butanedione Monoxime (BDM). 
 
3.2 The hypoxia-mediated repression of myofibroblast differentiation is accompa-
nied by changes in F-actin structures and RhoA activity 
3.2.1 F-actin assembly is distinctive in normoxia and hypoxia 
Besides the expression of αSMA, another defining feature of myofibroblasts is the assembly 
of pronounced, cell traversing stress fibers (Anderson et al., 2004). 
F-actin was characterised by phalloidin staining in PSF to evaluate the effect of oxygenation 
on the stress fiber network. In normoxia, αSMA-positive cells contained long, distinctive actin 
fibers crossing most of the cell (Fig. 10A, upper panel). By contrast, in non-αSMA-positive 
PSF cultured in hypoxia, actin filaments appear to be shorter and are predominantly present 
at the cell periphery (Fig. 10A, lower panel). These findings were quantified by using the non-
biased cluster analysis application MiToBo. Differences in structural patterns in the actin 
filaments form the basis for texture analysis with this application. Structural patterns with high 
similarity are defined as clusters. The F-actin quantification confirmed the varying F-actin 
structures of cells in normoxia and hypoxia by changes of cluster (C1-C6) distribution (Fig. 
10B).  
 
 
Figure 10: The hypoxia-mediated impairment of myofibroblast differentiation is paralleled by 
changes of F-actin structures. (A) F-actin of primary skin fibroblasts (PSF) was characterised in 
normoxia (20% O2) and hypoxia (1% O2) by phalloidin staining. PSF analysed in normoxia were 
αSMA-positive. Cells analysed in hypoxia were non-αSMA-positive. F-actin structures appeared to be 
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more pronounced in normoxic αSMA-positive cells, whereas hypoxic, non-αSMA-positive cells showed 
shorter F-actin structures predominantly in the cell periphery (left panels). The non-biased cluster 
analysis application MiToBo was applied to generate a pseudo coloured image of the F-actin cluster 
pattern (right panels). (B) Quantification of F-actin structures based on cluster (C1-C6) distribution 
analyses with MiToBo. At least n=11 cells per condition were analysed. Error bars represent mean ± 
SEM, p= ≤0.05. 
 
3.2.2 Hypoxia induces dynamic changes of RhoA activity 
The Rho GTPase RhoA plays a major role in the stress fiber induction and has been re-
ported to be involved in myofibroblast differentiation (Ni et al., 2013). 
To investigate if RhoA is involved in myofibroblast differentiation in normoxia, PSF were 
treated with the Rho inhibitor C3 transferase. Upon C3 transferase treatment, a reduction of 
αSMA- positive fibroblasts was observed compared to untreated fibroblasts in normoxia (Fig. 
11A and B). Due to its toxic feature, C3 treatment can lead to cell death. Hence, further 
analysis of αSMA expression, especially in hypoxia, was not possible. The decrease of 
αSMA-positive myofibroblasts upon C3 transferase treatment was similar to the effect of low 
oxygen concentration on myofibroblast differentiation shown in chapter 3.1.1. Therefore, fur-
ther experiments were performed to analyse the role of RhoA activity on oxygen-dependent 
myofibroblast differentiation.  
The effect of hypoxia on RhoA activity in PSF was investigated by performing Rho-GST pull-
down assays after 1, 4, 8, 12 and 24 h of hypoxic incubation, after having been plated and 
settled in normoxic conditions at least for 24 h (Fig. 11C). Upon hypoxic exposure, RhoA 
activity transiently increased, peaking at 4 to 12 h of hypoxia. Prolonged hypoxic exposure 
(24 h) resulted in a decrease of RhoA activity, similar to the basal level of RhoA activity in 
normoxia. 
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Figure 11: The hypoxia-mediated impairment of myofibroblast differentiation is paralleled by 
altered activity of RhoA. (A) Primary skin fibroblasts (PSF) cultured in normoxia (20% O2) treated 
with or without Rho inhibitor C3 transferase were stained for αSMA and F-actin. Upon C3 treatment, a 
reduction of αSMA-positive cells, in which αSMA colocalised with F-actin, was analysed. (B) αSMA-
positive PSF were quantified by counting. At least 100 cells per condition were analysed. Error bars 
represent mean ± SEM, p= ≤0.05. (C) RhoA activity was determined by GST-RBD pulldown experiments 
and immunoblotting analyses after incubating the cells in normoxia and hypoxia for the indicated time points. 
Hypoxia stimulated a transient increase of active RhoA (RhoA-GTP). Further hypoxic exposure leads to a de-
crease of RhoA activity similar to the normoxic control. Total amount of RhoA was unchanged in all conditions. 
Tubulin was used as a loading control. 
To further investigate the role of hypoxia on RhoA activity, the cell lines L929, originated from 
normal subcutaneous areolar mouse tissue, and MEF were used. These cell lines feature 
fibroblast phenotype characteristics and were used as a cell model. Active RhoA was deter-
mined by GST-RBD pulldown experiments. In hypoxia, RhoA activity increased progressively 
within a period of 15 min up to 1 h in both L929 cells and MEF (Fig. 12A and B). After 4 h to 
24 h of hypoxic exposure, RhoA activity declined. As expected, HIF-1α protein levels in-
creased over time, with a strong stabilisation after 4 h. Total RhoA protein levels did not 
change upon hypoxic incubation. Taken together, the analysed cell lines showed a similar 
RhoA activity pattern with a transient increase compared to PSF, albeit the RhoA activity in 
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fibroblast cell lines peaked earlier after the onset of hypoxia. To gain further mechanistic in-
sights into RhoA activity in hypoxia, the fibroblast (-like) cell lines L929 and MEF were used 
for follow-up experiments.  
 
 
Figure 12: Dynamic changes of RhoA activity in hypoxia in L929 fibroblasts and mouse embry-
onic fibroblasts (MEF). Active RhoA (RhoA-GTP) was determined by GST-RBD pulldown experi-
ments after incubation of L929 fibroblasts (A) and MEF (B) in normoxia (20% O2) or hypoxia (1% O2) 
for the indicated time. GST-RBD bound protein, and total cell lysates were analysed by immunoblot-
ting with the represented antibodies. Rapid, initial increase of RhoA activity within 15 min of reduced 
oxygen concentration was followed by a decrease of RhoA activity after extended hypoxic incubation 
in both of the cell lines. HIF-1α was stabilised and increased over time in hypoxia. Tubulin was ana-
lysed as a loading control. 
 
3.3 The Rho GTPase Activating Protein ArhGAP29 expression is induced in hypoxia 
Rho GTPases cycle between an active GTP and an inactive GDP bound form. This mecha-
nism is regulated by GEFs and GAPs (refer to chapter 1.4.2)  
To study the upstream regulation of RhoA activity in hypoxia, mRNA expression levels of 
several GAPs and GEFs were analysed by the laboratory of Prof. Katschinski (Leinhos et al., 
2019). For this purpose, several GAPs (ArhGAP1, ArhGAP5, ArhGAP18, ArhGAP19, Arh-
GAP21, ArhGAP29, ArhGAP35, GMIP, HMHA1, OPHN1, STARD13) and GEFs (ArhGEF1, 
ArhGEF10, ArhGEF11, ArhGEF15, ArhGEF18, Net1, Trio) with known impact on RhoA activ-
ity were selected. The mRNA expression levels of these GAPs and GEFs were analysed in 
L929 fibroblasts after 24 h of hypoxia. Upon hypoxia, a considerable amount of GAPs (Arh-
GAP5, ArhGAP18, ArhGAP19, OPHN1) and GEFs (ArhGEF1, ArhGEF15, Net1, Trio) were 
downregulated. Yet, only two GAPs were increased significantly (ArhGAP29 and Arh-
GAP35). Among these two upregulated GAPs, ArhGAP29 expression levels reached the 
most notable increase by more than 5-fold compared to a normoxic control.  
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Furthermore, the laboratory of Prof. Katschinski analysed the ArhGAP29 expression in dif-
ferent cell types after 24 h of hypoxic incubation. Besides, in L929 fibroblasts, hypoxic induc-
tion of ArhGAP29 expression was also noted in other murine cell lines such as C2C12, MEF 
as well as in primary cardiac fibroblasts and primary skin fibroblasts (Leinhos et al., 2019).  
 
3.3.1 ArhGAP29 dynamics are transiently induced in hypoxia 
A time course experiment on mRNA expression of ArhGAP29 in L929 fibroblasts was per-
formed by the laboratory of Prof. Katschinski (Leinhos et al., 2019). In this experiment, the 
mRNA expression levels of ArhGAP29 were analysed 1, 2, 4, 8, 12, 24, and 48 h after onset 
of hypoxia and compared to a normoxic control. ArhGAP29 was already induced 1 h after 
exposure to hypoxia and further increased after 4 h of hypoxia. After reaching the peak of 
hypoxic mRNA expression after 4 h, ArhGAP29 mRNA expression decreased with prolonged 
hypoxic incubation (8 h to 48 h). Increased protein levels of ArhGAP29 were detectable after 
4 h onset of hypoxia and further increased over time (8, 12 and 24 h).  
 
3.4 The hypoxic induction of ArhGAP29 is HIF-1α dependent 
To test if the hypoxic induction of ArhGAP29 is linked to the HIF pathway, stable HIF-1α 
knockdown clones of L929 fibroblasts (Vogler et al., 2013) were analysed. The hypoxic in-
duction of ArhGAP29 mRNA and protein levels were significantly reduced in L929 HIF-1α 
knockdown (Leinhos et al., 2019). I followed up these results and analysed ArhGAP29 ex-
pression in MEF derived originally from HIF-1α null (-/-) embryos (Ryan et al., 2000). Hypoxic 
induction of ArhGAP29 was detectable in MEF HIF-1α knockout cells (MEF -/-) on mRNA 
levels; however, it was significantly reduced compared to wildtype MEF (+/+) (Fig 13A). As 
expected, the expression of the known HIF-1 target gene PHD3 was reduced upon knockout 
of HIF-1α (Fig.13B). ArhGAP29 protein expression was decreased in MEF HIF-1α knockout 
cells compared to the wildtype control (Fig. 13C). Wildtype MEF (+/+) demonstrated a sub-
stantial increase of HIF-1α protein in hypoxia, whereas this increase was absent in MEF HIF-
1α knockout cells (MEF -/-) as expected (Fig. 13C).  
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Figure 13: Hypoxic induction of ArhGAP29 is linked to the HIF pathway. Wildtype MEF (+/+) and 
HIF-1α knockout MEF (-/-) were analysed. (A) Knockout of HIF-1α resulted in reduction of ArhGAP29 and 
(B) PHD3 mRNA as seen by qRT-PCR analyses. The mRNA expression levels were normalised to the 
housekeeping gene ms12 and are shown as fold change compared to the normoxic wildtype control. Three 
samples per condition were analysed. Error bars represent mean ± SEM, p= ≤0.05. (C) Immunoblot analysis 
showed that ArhGAP29 protein levels were reduced in HIF-1α deficient cells compared to wildtype cells. Vinculin 
was used as a loading control. 
 
3.5 Knockdown of ArhGAP29 impacts RhoA activity 
To investigate the functional role of ArhGAP29 in hypoxia, a shRNA mediated knockdown of 
ArhGAP29 in L929 fibroblasts was established by J. Peters in the laboratory of Prof. Ka-
tschinski. 
The knockdown of ArhGAP29 in L929 fibroblasts resulted in increased basal RhoA activity 
(RhoA-GTP) in normoxia compared to non-transduced controls (Fig. 14A and B). To investi-
gate the effect of ArhGAP29 deficiency on RhoA activity in hypoxia in detail, active RhoA 
was analysed in a hypoxia time course experiment (30 min, 4 h, and 24 h of hypoxic incuba-
tion). In contrast to the control cells, ArhGAP29 knockdown cells showed increased RhoA 
activity levels in normoxia and hypoxia (Fig. 14C and D). The observed increase of active 
RhoA in ArhGAP29 knockdown L929 fibroblasts was decreased after 24 h of hypoxia. Al-
though the RhoA activity pattern of ArhGAP29 knockdown cells was similar to L929 control 
cells, the activity kinetics were shifted. For example, RhoA activity declines after 4 h of hy-
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poxia in control cells, whereas in ArhGAP29 knockdown cells the RhoA activity is still in-
creased resulting in an overall longer-lasting activation of RhoA. 
 
 
Figure 14: Knockdown of ArhGAP29 in L929 fibroblasts results in increased RhoA activity.  
(A) Active RhoA (RhoA-GTP) was sedimented with GST-RBD beads from L929 control and ArhGAP29 
knockdown (kd) L929 fibroblasts cultured in normoxia (20% O2). Three independent pulldown experi-
ments were performed. The samples were loaded together with the respective total cell lysates on one 
SDS-gel and were analysed by immunoblotting using the indicated antibodies. Tubulin was used as a 
loading control. RhoA activity was increased in L929 ArhGAP29 kd cells compared to L929 control 
cells. (B) The Immunoblot band intensities shown in A were quantified with ImageJ. Band intensities of 
active RhoA were normalised to band intensities of total RhoA. The ratio active RhoA to total RhoA is 
shown. (C) L929 control and ArhGAP29 kd cells were incubated in normoxia (20% O2) and in hypoxia 
(1% O2 for 30 min, 4 h and 24 h). RhoA-GTP was sedimented in GST-RBD pulldown experiments and 
analysed by immunoblotting experiments together with total cell lysates with the indicated antibodies. 
The experiment was repeated four times; one representative experiment is shown. In the ArhGAP29 
kd cells the RhoA activity in hypoxia lasted longer than in the L929 control cells. (D) Quantification of 
active RhoA in L929 control and ArhGAP29 kd cells of the experiment described in C. Error bars rep-
resent mean ± SEM, p= ≤0.05. 
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3.5.1 F-actin formation is changed by knockdown of ArhGAP29  
Since RhoA is involved in the organisation of the actin cytoskeleton, the effect of ArhGAP29 
knockdown on F-actin structures in L929 fibroblasts was analysed. F-actin was visualised 
with phalloidin staining. F-actin structures were found to be more distinct in ArhGAP29 
knockdown L929 fibroblasts than in control cells (Fig. 15A). Further investigation with non-
biased cluster analysis using the MiToBo application affirmed the change of F-actin struc-
tures upon knockdown of ArhGAP29 in normoxia. The F-actin cluster distribution (C1-C6) 
was clearly diverse in control and ArhGAP29 knockdown L929 fibroblasts (Fig. 15B), indicat-
ing that the knockdown of ArhGAP29 leads to a remodelling process of the actin cytoskele-
ton.  
 
 
Figure 15: ArhGAP29 knockdown results in the remodelling of the actin cytoskeleton.  
(A) F-actin structures were analysed by phalloidin staining of L929 control and ArhGAP29 knockdown 
(kd) fibroblasts in normoxia (20% O2). Knockdown of ArhGAP29 resulted in increased F-actin forma-
tion. Magnification of a cell area (left panel). The area of magnification is indicated by the white boxes 
(middle panel). The F-actin patterns of control and ArhGAP29 kd fibroblasts were analysed with Mi-
ToBo. Highly similar structural patterns of F-actin were defined as clusters that were visualised by six 
colours in pseudo-coloured images (right panel). (B) Quantification of cluster (C1-C6) distribution. At 
least 50 cells per condition were analysed. Error bars represent mean ± SEM, p= ≤0.05. 
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3.5.2 MRTF-A localisation is altered in ArhGAP29 knockdown fibroblasts 
MRTF-A and SRF have been reported to be linked to RhoA signalling and thus to regulate 
the myofibroblast differentiation (Small et al., 2010; Velasquez et al., 2013). Enhanced F-
actin polymerisation promotes the nuclear import of MRTF-A and consequently the transcrip-
tion of target genes inducing the myofibroblastic programme (Velasquez et al., 2013). 
 
MRTF-A localisation was examined in L929 fibroblasts both in normoxia and hypoxia by im-
munofluorescence staining, using a specific MRTF-A antibody. In control cells, endogenous 
MRTF-A was localised mostly in the cytoplasm under normoxic conditions and did not show 
significant changes of localisation in hypoxia (Fig. 16). In contrast, endogenous MRTF-A was 
highly enriched in the nucleus both in normoxia and in hypoxia when ArhGAP29 was 
knocked down. To test, if the altered nuclear accumulation of MRTF-A was dependent on 
RhoA, cells were treated with the Rho inhibitor C3 transferase. Inhibition of RhoA by C3 
transferase resulted in a more cytoplasmic localisation of MRTF-A in the ArhGAP29 knock-
down cells. The cytoplasmic localisation of MRTF-A in ArhGAP29 knockdown cells was ob-
served both in normoxia and in hypoxia (Fig. 16A). For quantification, the ratio of nuclear 
localised MRTF-A and cytoplasmic localised MRTF-A was validated (Fig. 16B). Besides en-
dogenous MRTF-A, the localisation of exogenous GFP-tagged MTRF-A was analysed as well. 
The study of exogenous MRTF-A localisation showed results similar to endogenous MRTF-A. More 
nuclear localisation of exogenous, GFP-tagged MTRF-A was observed in ArhGAP29 knockdown 
cells in normoxia and hypoxia. Upon treatment with Rho inhibitor C3 transferase, exogenous nuclear 
MTRF-A was reduced (Fig. 16C and D).  
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Figure 16: ArhGAP29 knockdown results in enhanced nuclear localisation of MRTF-A.  
(A) Endogenous MRTF-A localisation was determined in L929 control and ArhGAP29 knockdown (kd) 
fibroblasts in normoxia (20% O2) and hypoxia (1% O2) by specific immunofluorescence staining. 
MRTF-A showed a stronger accumulation in ArhGAP29 kd cells. Nuclear MRTF-A accumulation was 
reduced upon Rho inhibitor C3 treatment. (B) For quantification of the experiments performed in A, the 
ratio of nuclear MRTF-A to cytoplasmic MRTF-A was determined. (C) GFP-tagged exogenous MRTF-
A localisation was analysed in L929 wt, and ArhGAP29 kd cells under the conditions described in A 
and similar results were obtained. (D) The ratio of nuclear GFP-tagged MRTF-A to cytoplasmic GFP-
tagged MRTF-A of the experiments described in C was determined for quantification. At least 36 cells 
per condition were analysed. Error bars represent mean ± SEM, p= ≤0.05. 
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3.5.3 ArhGAP29 knockdown results in altered SRE-dependent promoter activity and 
induction of MRTF-A/SRF target gene expression  
To further investigate the effects of ArhGAP29 on MRTF-A/SRF dependent signalling, lucif-
erase reporter gene assays were performed in L929 fibroblasts in order to determine SRE 
promoter activity. 
The knockdown of ArhGAP29 resulted in increased SRE-luciferase activity in normoxia and 
hypoxia (Fig. 17A). Furthermore, the MRTF-A/SRF target gene connective tissue growth fac-
tor (CTGF, also knowns as cellular communication network factor Ccn2) was induced signifi-
cantly in ArhGAP29 knockdown L929 fibroblasts in normoxia and hypoxia compared to con-
trol fibroblasts (Fig. 17B).  
 
 
Figure 17: SRE-dependent promoter activity and induction of MRTF-A/SRF target gene expres-
sion are altered upon knockdown of ArhGAP29. (A) SRE promoter activity was determined by the ratio 
of SRE driven firefly luciferase (FL) and renilla luciferase (RL). Knockdown (kd) of ArhGAP29 resulted in an 
increase of SRE promoter activity both in normoxia (20% O2) and hypoxia (1% O2). Data were compared to 
controls and are represented as fold change. (B) The MRTF-A/SRF target gene connective tissue growth 
factor (CTGF) mRNA expression was analysed by qRT-PCR. The CTGF mRNA expression levels 
were upregulated in ArhGAP29 kd L929 fibroblasts in normoxia and hypoxia. The mRNA expression 
levels were normalised to the housekeeping gene ms12 and are shown as fold change compared to 
the control. For each condition, at least three samples were analysed. Error bars represent mean ± SEM, 
p= ≤0.05. 
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3.6 The knockdown of ArhGAP29 in primary fibroblasts prevents the impairment of 
myofibroblast differentiation in hypoxia 
Experiments in the cell lines L929 and MEF revealed a link between the hypoxic induction of 
ArhGAP29 and the MRTF-A/SRF-RhoA signalling. L929 and MEF are a useful cell tool, dis-
playing fibroblast-like characteristics; however, these cells are not capable of a transition into 
myofibroblasts. Therefore, to further investigate if ArhGAP29 plays a role in myofibroblast 
differentiation in hypoxia, a knockdown of ArhGAP29 was established in PSF. 
 
The knockdown of ArhGAP29 via shRNA was verified by reduced mRNA expression levels 
of ArhGAP29 cells compared to controls (non-transduced and non-targeting shRNA control 
(shc), (Fig. 18A). The reduction of ArhGAP29 mRNA expression was observed in normoxia 
and hypoxia. The knockdown of ArhGAP29 in PSF resulted in an upregulation of αSMA in 
normoxia and hypoxia compared to respective controls cells. Hypoxia significantly reduced 
αSMA mRNA expression levels in control cells. However, this effect was decreased in Arh-
GAP29 knockdown PSF (Fig. 18B). In addition, immunofluorescence staining of αSMA was 
performed to further evaluate the impact of the knockdown of ArhGAP29 on the myofibro-
blast differentiation. The amount of αSMA-positive cells was reduced in hypoxia compared to 
normoxia in control cells (Fig.18C). However, hypoxia did not longer decrease the number of 
αSMA-positive cells upon knockdown of ArhGAP29 (Fig.18C). 
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Figure 18: Knockdown of ArhGAP29 prevents the hypoxia-mediated myofibroblast dedifferen-
tiation of primary fibroblasts. (A) Knockdown (kd) of ArhGAP29 was established in primary skin 
fibroblasts (PSF) and verified by qRT-PCR which showed reduced ArhGAP29 mRNA expression lev-
els in normoxia (20% O2) and hypoxia (1% O2). (B) The expression of αSMA was upregulated in Arh-
GAP29 kd PSF. The mRNA expression levels were normalised to the housekeeping gene ms12 and 
are shown as fold change compared to controls. Cells were isolated from six animals; data were 
pooled n=6.  
(C) αSMA-positive cells were quantified. Kd of ArhGAP29 resulted in increased αSMA-positive cells in 
normoxia and hypoxia. At least 200 cells per condition were analysed. Error bars represent mean ± SEM, 
p= ≤0.05. 
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4 Discussion 
Myofibroblasts are crucial for normal wound and tissue repair (Hinz, 2007). Wound healing is 
a highly complex process, in which tissue oxygenation plays an important role. Acute hypoxia 
stabilises HIF-1α and thus activates HIF-1 target genes restoring disrupted vascularisation 
and promoting tissue remodelling (Darby et al. 2014; Hong et al. 2014). Nonetheless, chronic 
hypoxia results in poor wound healing and finally tissue necrosis (Sen 2009). The Rho 
GTPase RhoA regulates stress fiber formation and is involved in myofibroblast differentiation 
through downstream MRTF/SRF signalling (Ni et al., 2013; Yuan et al., 2018). The regulation 
of RhoA activity and thus MRTF/SRF signalling in hypoxia has not been understood in detail 
so far.  
 
The laboratory of Prof. Katschinski identified that the expression of ArhGAP29, a regulator of 
RhoA activity, is induced in hypoxia. Based on these preliminary findings, the aim of this doc-
toral dissertation focused on testing the hypothesis that ArhGAP29 plays an important role in 
regulating RhoA activity and the MRTF/SRF-mediated myofibroblast differentiation pro-
gramme in hypoxia. 
 
In this study, it was shown that the myofibroblast differentiation is impaired by hypoxia. The 
suppressed myofibroblast differentiation in hypoxia was accompanied by reduced αSMA 
expression, limited contractile forces, cytoskeletal alterations and decreased RhoA activity. 
ArhGAP29 was identified to play an essential role in fine-tuning RhoA activity in hypoxia and 
thus to regulate downstream signalling such as the MRTF/SRF pathway, the principal 
inducer of the myofibroblast programme and fibrotic response. Taken together, this study 
revealed ArhGAP29 as a novel link between the RhoA-MRTF/SRF pathway and HIF-
signalling. 
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4.1 Hypoxia is a negative modulator of myofibroblast differentiation and function 
The differentiation of fibroblasts to contractile, ECM-producing myofibroblasts is essential for 
wound healing and tissue remodelling (Bochaton-Piallat et al., 2016). Dysregulation of 
myofibroblast activity leads to irreversible fibrotic diseases as well as tissue and organ mal-
function (Klingberg et al., 2013). Hypoxia and HIF signalling are critically involved in tissue 
remodelling and normal wound healing as well as in myofibroblast-mediated diseases, such 
as fibrosis.  
 
In this study, I was able to demonstrate that hypoxia has a suppressive effect on myofibro-
blast differentiation. The observed myofibroblast phenotype of primary fibroblasts cultured in 
normoxic conditions was reversed in hypoxia. Signature myofibroblast markers, such as 
αSMA and Tagln, were downregulated upon prolonged incubation in low oxygen concentra-
tion. The overall actin filament organisation was affected in hypoxia and αSMA was no longer 
intercalated in F-actin. Furthermore, hypoxic primary cells showed less ability to contract a 
collagen matrix, which is in line with the decreased expression of αSMA. The fibroblast to 
myofibroblast transition is complex and involves the orchestrated interplay of many factors 
and mechanisms. Mechanical stress promotes the myofibroblast differentiation. It is widely 
reported that substrate stiffness influences cell morphology and function, for example, rigid 
surfaces can promote stress fiber formation in cultured fibroblasts (Georges and Janmey, 
2005; Discher et al., 2005; Solon et al., 2007). The primary fibroblasts used in this study 
were cultured on rigid cell culture plastic surfaces; hence, this might have promoted the ob-
served fibroblast to myofibroblast transition in normoxia. However, exposure to hypoxia led to 
a regression of the observed myofibroblast phenotype indicating that mechanical stress is 
not enough to fully initiate the myofibroblast differentiation (Darby et al., 2014). 
The myofibroblast differentiation was further enhanced by the addition of TGF-β, a known 
driver of this differentiation. In hypoxia, the cellular response to TGF-β was diminished. The 
suppressive effect of hypoxia on TGF-β stimulation was also described in corneal keratocyte 
myofibroblast differentiation (Xing and Bonanno, 2009). The described findings indicate that 
in addition to mechanical stress and cytokine stimulation, other molecular mechanisms are 
involved in the myofibroblast differentiation. Hypoxia-mediated impairment of myofibroblast 
differentiation in vitro, as seen in the presented project, has been described in rat subcuta-
neous and cardiac fibroblasts (Modarressi et al., 2010). In contrast, exposure of lung and 
liver fibroblasts to hypoxia resulted in increased myofibroblast differentiation, indicating that 
the tissue origin might be decisive for the hypoxic effect on the myofibroblast differentiation 
state. To understand these divergent findings, it is crucial to be aware of the variable pO2 at 
tissue level in vivo and carefully compare these to cell culture conditions. The physiological 
pO2 is widely diverse in tissue and organs and never reaches the atmospheric pO2 of ap-
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proximately 140 mm Hg at sea level. Hence, every cell has a defined individual, origin-
dependent normoxic state, that is characterised by the lack of initiation of the cellular hypoxic 
response (Sen, 2009; Carreau et al., 2011). Standard cell culture conditions rely on the pO2 
of ambient air. Therefore, freshly isolated primary fibroblasts experience a dramatic increase 
of oxygen when first introduced to standard cell culture conditions (Sen and Roy, 2010; Mo-
darressi et al., 2010). The excess supply of oxygen, also referred to as hyperoxia, was re-
ported to initiate primary cardiac fibroblasts transdifferentitaion to myofibroblasts (Roy et al., 
2003). However, the primary cells used in the presented experiments were cultured for at 
least one week at 20% O2 before they were used for further experiments. This most likely 
allowed them to adjust to the normoxic cell culture conditions and reset their normoxic set 
point. This was suggested by their ability to stabilise HIF-1α under experimental hypoxic 
conditions. Therefore, hyperoxia is unlikely to have triggered the observed normoxic 
myofibroblast differentiation.  
 
A contribution of the Rho signalling pathway, particularly the involvement of RhoA, to the 
differentiation process of myofibroblasts has also been taken into consideration (Ni et al., 
2013; Jatho et al., 2015). The presented study supports the involvement of RhoA in 
myofibroblast differentiation, as cell treatment with the Rho inhibitor C3 transferase in nor-
moxia resulted in the reduction of αSMA-positive, cell traversing stress fibers. Thus, these C3 
transferase-treated normoxic cells displayed a cytoskeletal organisation similar to a hypoxic 
cell. Indeed, when analysing Rho activity of primary fibroblasts after prolonged hypoxic incu-
bation, a decrease of RhoA activity, accompanied by a decrease of αSMA was found. 
It has been reported that myofibroblasts are deactivated or disappear by apoptosis or re-
gression after successful tissue repair (Desmoulière et al., 1995; Hecker et al., 2011; Kisse-
leva et al., 2012). The molecular events underlying myofibroblast regression have not been 
understood in detail yet. The results presented in this thesis imply that hypoxia promotes this 
regression and suggest a role of RhoA in this process. 
 
4.2 ArhGAP29 is a regulator of RhoA activity in hypoxia 
To investigate how RhoA activity is controlled in hypoxia, the laboratory of Prof. Katschinski 
analysed the expression of several GEFS and GAPs with known activity towards RhoA. 
ArhGAP29, a suppressor of RhoA activity, was identified by J. Peters (laboratory of Prof. 
Katschinski) to be expressed in an oxygen-dependent manner. As ArhGAP29 is involved in 
cytoskeletal organisation, ArhGAP29 expression levels need to be tightly controlled. Re-
duced ArhGAP29 expression results in remodelling of the actin cytoskeleton and abnormal 
embryonic development in mice (Xu et al., 2011; Barry et al., 2016; Paul et al., 2017). Fur-
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thermore, humans with mutant ArhGAP29 suffer from NSCL/P congenital disabilities (Leslie 
et al., 2012; Butali et al., 2014; Chandrasekharan and Ramanathan, 2014; Paul et al., 2017; 
Liu et al., 2017). 
The hypoxic induction of ArhGAP29 was shown to be HIF-1α dependent. Several potential 
HIF-1 binding sites (HREs) exist within the ArhGAP29 promoter region; however, further 
analyses are needed to test if the HIF-1 binding sites are functional. To test this chromatin 
immunoprecipitation or electrophoretic mobility shift assays can be used. YAP, which can be 
induced in hypoxia, has been shown to be a regulator of ArhGAP29 expression (Dai et al., 
2016; Qiao et al., 2017). Therefore, YAP could contribute to the expression of ArhGAP29 in 
hypoxia. In contrast to ArhGAP29, YAP induction is not mediated by HIF-1α (Dai et al., 
2016). This argues against a role of YAP in the transcription of ArhGAP29 in hypoxia. In ad-
dition to its expression levels, YAP activity is controlled by its cellular localisation. YAP is 
active when in the nucleus, and inactive in the cytoplasm. Cytoplasmic retention of YAP re-
sults in the inhibition of transcription of target genes (Low et al., 2014; Das et al., 2016). To 
further investigate whether YAP plays a role in the hypoxic induction of ArhGAP29, the local-
isation of YAP in hypoxia needs to be analysed.  
The ArhGAP29 knockdown experiments presented in this study demonstrate that ArhGAP29 
regulates RhoA activity in normoxia and hypoxia in fibroblasts. Reduction of ArhGAP29 ex-
pression resulted in increased RhoA activity and increased stress fiber formation both in 
normoxia and in hypoxia. The RhoA kinetics were shifted in hypoxia and RhoA remained 
active for longer in ArhGAP29 kd cells. However, it should be noted that the knockdown of 
ArhGAP29 did not completely prevent the reduction of RhoA activity in hypoxia. Considering 
that there are more than 66 different human GAPs known it is likely that other GAPs are in-
volved in the hypoxic regulation of RhoA (Amin et al., 2016). In addition, the possibility that 
the approximately 24 GEFs associated with RhoA play a role in balancing RhoA activity in 
hypoxia has not been excluded (Rossman et al., 2005).  
 
It should be noted that the observed decrease of RhoA activity in hypoxia followed a prior 
rapid but transient increase of RhoA activity. The molecular mechanism underlying this fast 
increase in RhoA activity at the beginning of hypoxic incubation cannot be explained by the 
presented results. Throughout the literature, conflicting data about the influence of hypoxia 
on RhoA activity are found, and both increase and decrease of RhoA activity in hypoxia have 
been reported (Zieseniss, 2014). However, this study shows that RhoA activity changes over 
time in hypoxia, which could explain the controversial results.  
  
Discussion 
63 
4.3 RhoA activity and MRTF-A signalling are modulated by ArhGAP29 expression in 
hypoxia 
The knockdown of ArhGAP29 resulted in increased RhoA activity in line with enhanced 
stress fiber formation both in normoxia and in hypoxia. These cellular actin dynamics are 
linked to the MRTF/SRF signalling pathway (Olson and Nordheim, 2010). The nuclear import 
of MRTF-A, and consequently the activation of MRTF/SRF target genes, requires the RhoA 
mediated turnover of G-actin to F-actin (Olson and Nordheim, 2010; Small, 2012). Enhanced 
nuclear localisation of MRTF-A was observed in ArhGAP29 knockdown cells in normoxia and 
hypoxia. The nuclear accumulation of MRTF-A was reversible upon Rho inhibition. The 
MRTF/SRF signalling pathway is known to play an important role in regulating the 
myofibroblast programme (Small, 2012). Thus, the knockdown of ArhGAP29 not only had an 
impact on the actin cytoskeleton but also on RhoA dependent signalling.  
MRTF-A deficient mice show impaired myofibroblast differentiation associated with reduced 
scarring after myocardial infarction, whereas the activation of the MRTF-A pathway via small 
molecules has been reported to be beneficial for wound healing (Small et al., 2010; Ve-
lasquez et al., 2013). Thus, targeting the MRTF-A pathway could be a promising strategy in 
treating fibrotic diseases associated with inappropriate myofibroblast activity. 
In this dissertation, a novel link between ArhGAP29 and the RhoA-F-actin-MRTF/SRF signal-
ling pathway in hypoxia was discovered, indicating a possible therapeutic approach for tar-
geting myofibroblasts, specifically in hypoxic tissue. Growing evidence suggests that GAPs 
could be druggable targets and small molecular modulators of GAPs could be developed 
(Vigil et al., 2010). The pharmacological manipulation of GAPs has already been considered 
for cancer therapy; however, this concept requires further research (Vigil et al., 2010). 
In light of the presented data, manipulating RhoA activity to prevent fibrosis indirectly by ad-
dressing the HIF pathway could provide a new potential therapeutic approach. Small mole-
cule inhibitors of the PHD enzymes can activate HIF-signalling and have been extensively 
used in clinical studies in treating renal anaemia (Katschinski, 2009; Haase, 2017). When 
treating cells with the PHD inhibitor DMOG, the laboratory of Prof. Katschinski could show 
that ArhGAP29 is also affected when the HIF system is activated in normoxia. Thus, target-
ing RhoA signalling via PHD inhibitors could a feasible approach. 
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4.4 Conclusion and outlook 
Although myofibroblasts are crucial for normal wound healing and tissue remodelling due to 
their contractile function, excessive myofibroblast activity can cause pathological tissue dys-
function (Hinz, 2007). In this dissertation, a connection between the RhoA-MRTF/SRF signal-
ling pathway and the master regulator of the hypoxic response (HIF-1) was described. The 
presented data highlight the important regulatory role of ArhGAP29 in fine-tuning RhoA de-
pendent myofibroblast programme in hypoxia. 
 
A myofibroblast phenotype accompanied by an increase of αSMA and pronounced stress 
fibers was observed in primary fibroblasts cultured in normoxia. In contrast, hypoxia initiated 
the HIF-1α-dependent induction of ArhGAP29, which inhibited RhoA activity and conse-
quently MRTF/SRF signalling. Hypoxia impaired myofibroblast differentiation, as seen by 
reduced stress fiber formation and restricted αSMA expression. The knockdown of Arh-
GAP29 prevented the myofibroblast regression in hypoxia, because the knockdown in-
creased RhoA activity and thus activated the MRTF/SRF pathway and the myofibroblast pro-
gramme (Fig. 19). 
 
The oxygenation state as a driver for fibroblast to myofibroblast differentiation is controver-
sially discussed in the scientific community (Modarressi et al., 2010; Zhao et al., 2017). Albeit 
Modarressi et al. (2010) assumed a role of RhoA signalling in hypoxia-mediated suppression 
of myofibroblast differentiation, the underlying potential pathway was not further investigated. 
This study adds to the understanding of the pathway and describes a connection between 
hypoxia-mediated suppression of myofibroblasts and RhoA-MRTF/SRF signalling via Arh-
GAP29. Thus, targeting ArhGAP29 may lead to new therapeutic strategies to approach 
pathophysiological conditions involving myofibroblast dysfunctions, such as fibrosis or poor 
wound healing. The pharmacological manipulation of GAPs has already been considered for 
cancer therapy; however, the concept remains in an early stage of research (Vigil et al., 
2010). Addressing the HIF pathway by small molecule inhibitors of the PHD enzymes seems 
to be a promising therapeutic approach (Katschinski, 2009). The laboratory of Prof. Ka-
tschinski was able to demonstrate induction of ArhGAP29 in normoxia after pharmacological 
PHD inhibition via DMOG. 
Interestingly, hypoxic induction of ArhGAP29 was not limited to one cell type, and for exam-
ple, it was also observed in primary cardiac fibroblasts by the laboratory of Prof. Katschinski. 
Regarding the important role of myofibroblasts in the remodelling response of the ischemic 
heart, it would be of high interest to investigate the role of ArhGAP29 in the context of car-
diac tissue remodelling and scarring. Preliminary, unpublished data of Prof. Katschinski´s 
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laboratory allowed first evidence that ArhGAP29 protein levels were elevated in murine 
hearts after myocardial infarction.  
Taken together, the presented data contribute to a better understanding of the complex mo-
lecular mechanisms of the RhoA-MRTF/SRF signalling axis in hypoxia and thus add insights 
to the highly orchestrated fibroblast to myofibroblast differentiation process. Finally, these 
findings may provide approaches for new therapeutic strategies targeting pathological condi-
tions of abnormal scarring and wound healing. 
Figure 19: Illustrated summary of the role of ArhGAP29 in myofibroblast differentiation under 
hypoxic conditions. Cultivation of fibroblasts in normoxia (20% O2) leads to the development of 
αSMA-positive actin filaments. Hypoxia reverts the myofibroblast phenotype observed in normoxia. 
HIF-1α-dependent expression of ArhGAP29 decreased RhoA activity and impaired the MRTF/SRF 
pathway and thus αSMA expression. The knockdown of ArhGAP29 prevents the hypoxia-mediated 
myofibroblast repression.  
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